A

ABO incompatibility, hemolytic disease due to, 521

Abortion
in amiodarone use, 171
amniotic fluid embolism following, 356
association with maternal congenital heart disease, 184
in diabetic parturients, 339
in disseminated intravascular coagulation, 318–319
in Eisenmenger’s syndrome, 187
in hemoglobin Bart’s hydrops fetalis management, 262
in maternal hyperparathyroidism, 222–223
in maternal tetralogy of Fallot, 186
in primary pulmonary hypertension, 189
with propranolol use, 219
rate of, in smokers, 150, 407
in renal disease, 210
in renal transplant patients, 211
in α-thalassemia, 260, 323
in tobacco use, 425
venous air embolism following, 361
in warfarin use, 183
See also Fetal loss/death

Abruptio placentae
antepartum hemorrhage in, 89–94
as a cause of third trimester hemorrhage, 87
in smokers, 150
Abscess, epidural, incidence of, 435
Achondroplasia, 236
Acid-base physiology, fetal
acidemia, association with spinal anesthesia, 498
acidosis
anesthetic contribution to, 342
from hyperinsulinemia, 334
metabolic, response to, 19
assessing, 494
See also Acidosis/alkalosis

Acidosis/alkalosis
maternal, effect on urterine and umbilical blood flow, 38–39
pH of fetal scalp blood, correlation with fetal heart rate pattern, 19
pH of umbilical arterial blood, in obese women, 56–57
pregnancy-induced, 207
respiratory, 4
fetal, due to decreased carbon dioxide elimination, 6
fetal, from maternal hypercapnia, 148
See also Acid-base physiology, fetal
Activated partial prothrombin time (aPTT), 371
following, to modify heparin use before delivery, 373
Acute fatty liver of pregnancy (AFLP), 473–474, 511
mortality in, 463
in preeclampsia, 281
Acute hepatic failure, in pregnancy, 469–470
Acute interstitial necrosis (AIN), acute renal failure due to, 208–209
Acute left heart failure, differentiating from amniotic fluid embolism, 358
Acute normovolemic hemodilution (ANH), 99–100
Acute renal failure (ARF), 208–209
in placental abruption, 92–93
Acute respiratory distress syndrome (ARDS), 507
Acute tubular necrosis (ATN), acute renal failure due to, 208–209
Acylovir
for herpes simplex virus infection, 393–394
for varicella zoster virus infection, 399
Adaptation, cardiovascular, during gestation, 155–158
Addiction
defined, 403
and drug use in pregnancy, 404–410
See also Drug abuse
Addison disease, 224–225
Adenomas
parathyroid, and hyperthyroidism in pregnancy, 223
pituitary
Cushing’s disease due to, 225
prolactin-secreting, 228–229
Adenosine
for treating atrial tachycardia, 168–169
for treating paroxysmal supraventricular tachycardia, 170–171
Adrenalectomy, for pheochromocytoma, in the second trimester, 197
Adrenal gland disease, 224–226
Adrenergic agonists
α-, for managing asthma during pregnancy, 146
β-, for maternal hypotension management, 495–496
for preterm labor management, 293
β2-, for managing asthma during pregnancy, 145
for tocolysis, physiologic responses to, 297–298
Adrenocorticotropic hormone (ACTH), effect of, on fetal breathing movements, 5
Adult respiratory distress syndrome (ARDS), 147–148
in pyelonephritis during pregnancy, 439–440
Advisory Committee on Immunization Practices (ACIP), on hepatitis B screening for pregnant women, 477
Age, maternal, and incidence of amniotic fluid embolism, 355
Agglutinin disease, cold, effects of cool operating rooms on, 276
AIDS Clinical Trials Group (ACTG), on antiviral medications for parturients, 392
AIDS-dementia complex (ADC). See Human immunodeficiency virus (HIV) infection
Air embolism
differentiating from amniotic fluid embolism, 358
venous, 360–363
Airway changes, 505
with obesity, 54
during parturition, 124
with pregnancy, 88
Airway management
difficulty with, in pregnancy, 507
fetal, obstruction of, 37
Alimentary aminotransferase (ALT), as an indicator of hepatocellular dysfunction, 465
Albumin, infusion of, for pregnant patients with hepatic disease, 467–468
Albuminuria, effects of, on pharmacokinetics of protein-bound drugs, 212
Alcohol
association with fetal death, 515, 522
liver disease from use of, 481
Aldosterone, depression associated with use of, 448
Aldosterone, effects of, on heart rate, 5
systemic, 224
Algorithms
for breech delivery, 72
for emergency cesarean section, 499
for regional anesthesia in the heparinized parturient, 373
for β-thalassemia management, 258
Alkaline phosphatase, levels of, in the third trimester of pregnancy, 463
Alkalosis. See Acidosis/alkalosis
Alloimmune thrombocytopenia (AIT), on alloimmune thrombocytopenia, 316
American Heart Association
on prophylactic antibiotic use, in mitral valve prolapse, 176
on resuscitation protocols, 167
American Society of Anesthesiologists (ASA), guidelines of
for blood component therapy, 524–525
for conservation of blood and blood products, 98
for managing unexpected airway difficulty, 62
Aminoglycosides, effects of, on the fetus, 434
Amiodarone
for controlling ventricular rate, in patients with atrial fibrillation or flutter, 168
risks and benefits of use in pregnancy, 171
Ammonia, metabolism of, and liver dysfunction, 465
Anemia
Alphablockers, for managing pheochromocytoma in pregnancy, 227–228
Alpha fetoprotein (AFP), measuring to detect fetal anomalies, 10, 25
Amanita phalloides mushrooms, hepatotoxins of, 475
American Academy of Pediatrics (AAP), on hepatitis B screening for pregnant women, 477
American College of Obstetricians and Gynecologists
on adolescent pregnancy, 451
on cesarean delivery after maternal cardiopulmonary arrest, 243
definition of postpartum hemorrhage by, 112
on epidural anesthesia for external cephalic version, 73
on heparin administration for deep venous thrombosis, 372
on hepatitis B screening for pregnant women, 391, 477
Intrapartum Fetal Heart Rate Monitoring, Technical Bulletin on, 494
preeclampsia definition by, 325
on screening for gestational diabetes, 340
on seat belts for pregnant women, 239–240
American Heart Association
on prophylactic antibiotic use, in mitral valve prolapse, 176
on resuscitation protocols, 167
American Society of Anesthesiologists (ASA), guidelines of
for blood component therapy, 524–525
for conservation of blood and blood products, 98
for managing unexpected airway difficulty, 62
Aminoglycosides, effects of, on the fetus, 434
Amiodarone
for controlling ventricular rate, in patients with atrial fibrillation or flutter, 168
risks and benefits of use in pregnancy, 171
Ammonia, metabolism of, and liver dysfunction, 465
Anemia
Alphablockers, for managing pheochromocytoma in pregnancy, 227–228
Alpha fetoprotein (AFP), measuring to detect fetal anomalies, 10, 25
Amanita phalloides mushrooms, hepatotoxins of, 475
American Academy of Pediatrics (AAP), on hepatitis B screening for pregnant women, 477
American College of Obstetricians and Gynecologists
on adolescent pregnancy, 451
on cesarean delivery after maternal cardiopulmonary arrest, 243
definition of postpartum hemorrhage by, 112
on epidural anesthesia for external cephalic version, 73
on heparin administration for deep venous thrombosis, 372
on hepatitis B screening for pregnant women, 391, 477
Intrapartum Fetal Heart Rate Monitoring, Technical Bulletin on, 494
preeclampsia definition by, 325
on screening for gestational diabetes, 340
on seat belts for pregnant women, 239–240
American Heart Association
on prophylactic antibiotic use, in mitral valve prolapse, 176
on resuscitation protocols, 167
American Society of Anesthesiologists (ASA), guidelines of
for blood component therapy, 524–525
for conservation of blood and blood products, 98
for managing unexpected airway difficulty, 62
Aminoglycosides, effects of, on the fetus, 434
Amiodarone
for controlling ventricular rate, in patients with atrial fibrillation or flutter, 168
risks and benefits of use in pregnancy, 171
Ammonia, metabolism of, and liver dysfunction, 465
Anemia
Alphablockers, for managing pheochromocytoma in pregnancy, 227–228
Alpha fetoprotein (AFP), measuring to detect fetal anomalies, 10, 25
Amanita phalloides mushrooms, hepatotoxins of, 475
American Academy of Pediatrics (AAP), on hepatitis B screening for pregnant women, 477
American College of Obstetricians and Gynecologists
on adolescent pregnancy, 451
on cesarean delivery after maternal cardiopulmonary arrest, 243
definition of postpartum hemorrhage by, 112
...
of amphetamine users, 423
in ankylosing spondylitis, 274
in anticoagulation medication patients, 375–377
in antiphospholipid antibodies syndrome, 269, 325
in aortic coarctation, uncorrected, 195
in aortic insufficiency, 178–179
in aortic stenosis, 178
in asthma, 146–147
in autoimmune hemolytic anemia, 276
of barbiturate-addicted patients, 413
in Bernard–Soulier syndrome, 314–315
of cocaine users, 422
in cerebrovascular disease, 162–166
in cardioversion, 172
in cerebral hemorrhage, 139
in chorionic villus sampling, 438
in common neuropathies, 140–141
in complicated pregnancies, 1
in critical care, for high-risk parturients, 505–514
in cystic fibrosis, 150–156
in dermatomyositis/polymyositis, 271–272
for diabetic parturients, 341–342
in disseminated intravascular coagulation, 319
in drug addiction, 409–410
in Eisenmenger’s syndrome patients, 187–189
in electroconvulsive therapy management, 454
in epilepsy, 135
in factor XI deficiency, 321
in the febrile parturient, 434–437
in fetal distress, 497–501
in fetal interventions, 38–41
in gallstone-related disease, 483
in gestational thrombocytopenia, 310–311
in Glanzmann’s thrombasthenia, 315
in group B β-hemolytic streptococcus infection, 386–389
in heart transplant patients, 198
in HELLP syndrome, 317–318, 473
in hemoglobin Bart’s hydrops fetalis, delivery of the fetus, 262
in hemolytic uremic syndrome and thrombotic thrombocytopenia purpura, 318
for hemophilia A carriers, 320
in hepatic disease, 467–469
in hepatic failure, fulminant, 480–481
in hepatic hematoma, 472
in hepatitis infection, 391, 442–443, 477
in herpes simplex virus infection, 394, 438–439
in human immunodeficiency virus infection, 392, 441–442
in hyperadrenocorticism, 225–226
in hypercoagulable syndromes, 326–328
in hyperemesis gravidarum, 482
in hyperparathyroidism, 223
in hypertrophic cardiopathy, 173
in hypoadrenocorticism, 225
in hypoparathyroidism, 224
in hypothyroidism, 221–222
in idiopathic thrombocytopenic purpura, 275, 311–312
in infection, 382
in intrahepatic cholestasis of pregnancy, 482
in intrauterine fetal demise management, 523–524
in iron deficiency anemia, 322
in late-stage syphilis, 397
in liver failure, acute, 470
in liver transplantation in pregnancy, 485–486
in lower back pain, 234
in Lyme disease, 395
in malignant hyperthermia, 443
in Marfan syndrome patients, 194–195
in marijuana use, 417
in mitral regurgitation, 178
in mitral stenosis, 182
in mitral valve prolapse, considerations in complicated pregnancies, 176–177
in multiple gestations, 82–84
in multiple sclerosis, 134–135
in myasthenia gravis, 136, 270–271
in myocardial infarction, 192–194
in myotonic disorders, 137
of narcotics users, 415–416
in obese patients, 57–63
in panhypopituitarism, 230
in peripartum cardiomyopathy, 175
of phenycyclidine users, 424
in pheochromocytoma, 227–228
in pituitary gland disease, 229
in placenta accreta, 103–104
in placental abruption, 91–92
in placenta previa, 97–98
in pneumonia in pregnancy, 440
in postdate pregnancy and delivery, 304–305
in postpartum hemorrhage, managing, 123–125
in preeclampsia, 286–287
in preterm labor, 295–299
in primary pulmonary hypertension patients, 189–190
in prolactinoma, 229
and psychotropic drug use in pregnancy, 454–460
in pulmonary embolism, 350–352
in renal disease, 211–214
in rheumatoid arthritis, 266
in scleroderma, 273
in scoliosis, 235–236
in septic shock, 441
in sickle cell disease, 322–323
specific fetal conditions affected by, 28–30
in spinal cord injury, 138
in systemic lupus erythematosus, 268
in Takayasu arteritis, 195
in teenage pregnancies, 48–49
in tension or migraine headaches, 134
in tetralogy of Fallot, maternal, 186
in thalassemia, 323
in thromboembolism, 353–354
in thyrotoxic patients, 220
in tobacco smoking, 426
in toxoplasmosis, evaluation of clotting parameters, 397–398
in trauma to the pregnant woman, 241–242
in tuberculosis patients, 398
in urinary tract infection, in pregnancy, 440
in uterine atony, 102
in varicella zoster virus infection or reactivation, 399
in venous air embolism, 362–363
in von Willenbrand’s disease, 314
Anesthetics
choice of
in hepatic disease, 466, 468
for preterm delivery, 296–297
halogenated, as a trigger for malignant hyperthermia, 247
interactions with tricyclic antidepressants, 455
Aneuploidies, chromosomal, detecting, 27
Aneurysm, cerebral, management of during pregnancy, 139
Angiotensin-converting enzyme (ACE) inhibitors
contraindications to use of during pregnancy, 174–175, 282–283
for renal crisis management, 272
Animal studies
of amphetamine use in pregnancy, 423
cocaine effects on the fetus, 422
in pregnancy, 419
of narcotic effects on the fetus, 414, 422
Ankylosing spondylitis, 273–274
Anomalies. See Congenital abnormalities/anomalies
Antibiotic prophylaxis
for cesarean delivery after trauma to the pregnant woman, 241–242
for infective endocarditis, in women with cardiovascular disease, 162
for outflow obstruction patients during labor and delivery, 173
before regional anesthesia, in patients with infections, 382
Antibody-dependent cell-mediated cytotoxicity (ADCC), corticosteroids for treating, 275
Anticardiolipin antibodies (ACA) association with pregnancy loss, 268, 519–520
diagnosis of hypercoagulation using, 371 role in hypercoagulable syndromes, 324–325

B Bacille Clamette-Guérin (BCG) vaccine, effect on tuberculosis in children, 398 Backache, 233–234 Bacterial infections, maternal, not specific to pregnancy, 439–441 Bacteriuria, asymptomatic rate of progression to clinical infection in pregnancy, 210 treating in pregnancy, 387 Barbitalures, addiction to, in pregnancy, 413 Baroreflex, fetall, 3 Becker’s muscular dystrophy, transmission patterns, 137 Beclomethasone, for managing asthma during pregnancy, 145 Bell’s palsy, 140 Benodiazepines clefts associated with diazepam use, 459 maternal and neonatal effects of use of, 416 Bernard-Soulier syndrome, 314–315 Beta-adrenergic agents, effects of, in uterine atony, 121
Index

Beta-agonists, effects of, in trauma to the pregnant woman, 242
Beta-blockers
  for atrial tachycardia management, 168
  for cardiac arrhythmia treatment, 171, 176
  for pheochromocytoma management, in pregnancy, 227
  for Takayasu arteritis treatment, 195
  for thyroid crisis management, 213
Bleeding time test, 287
Bleeding, into the spinal canal, as a cause of fetal loss, 517
Birthrate, age-specific, 45–47
Birth defects, due to substance abuse by mothers, 407. See also Congenital abnormalities/anomalies
Birthrate, age-specific, 45–47
Bleeding, into the spinal canal, as a complication of spinal or epidural anesthetics, 375. See also Hemorrhage
Bleeding time test, 287
Predictive value of, in epidural hematoma formation, 377
Bone marrow transplantation, allogeneic, in postdate pregnancy, 304
for autologous, 126
Bone marrow transplantation, autologous, 126
Blood sampling
  for fetal, 494
  maternal, to identify congenital fetal disorders, 25
Blood components
  changes in, during pregnancy, 89, 237–238
  gas measurements, changes in values during pregnancy, 143
Blood flow
  placental, effect of drug abuse on, 406
  maternal, during pregnancy, 505
Blood pressure
  changes in, during pregnancy, 88–89, 157, 505
  managing, during anesthesia in pheochromocytoma patients, 228
  monitoring during labor and delivery, 57–60
  in cardiovascular disease patients, 163
  effect of anesthetics on, 286–287
  in Marfan syndrome patients, 194
See also Hypertension; Hypotension
Blood sampling
  fetal, from the scalp, 494
  maternal, to identify congenital fetal disorders, 25
Blood transfusion
  alternatives to, in obstetric patients, 98–100
  autologous, 126
  Blunt trauma, causes of, 239–240
  B-Lynch procedure, for managing uterine atony, 101–102
  Body mass index (BMI) defined, 53
    maternal, correlation with cesarean delivery, 305
  Body movements, fetal, and fetal heart rate, 6
  Bohr effect, relationship between partial pressure of oxygen and pH, 4
  Bone marrow transplantation, autologous, for managing β-thalassemia, 261
  Bone metabolism, in hyperadrenocorticism, 225–226
  Borrelia burgdorferi, infection by, 394–395
    as a cause of fetal loss, 517
  Brachial plexus palsy, association with shoulder dystocia, 306
  Bradycardia, fetal
    association with hypoglycemia, 337
    after esmolol use, 283
    as a response to aortic insufficiency, 179
    to hypoxia or asphyxia, 14
  Brain
    early involvement of, in human immunodeficiency virus infection, 391
    fetal, maintenance of oxygen delivery to, 493
    neoplasms of, 138–139
  Brazelton Neonatal Behavioral Assessment Scale, 414
Breathing
  fetal, 5–6
  maternal, alteration during pregnancy, 88
See also Respiratory entries
Breech presentation, 67–70
  cesarean versus vaginal delivery in, 295–296
  Bromocriptine, for managing prolactinomas, 229
  Bronchitis, managing in pregnancy, 148
  Bronchodilatators, for managing asthma during pregnancy, 145
  Bronchopulmonary sequestration (BPS), diagnosis of, 34
  Brow presentation, 76–77
  Bupivacaine
    for analgesia in labor, with a breech presentation, 74
    effect of, on the preterm fetus, 296
  Burn injuries, in pregnancy, 240–241, 510–511
  C
  Calcium
    effect of, on preeclampsia risk, 285
    maintenance of homeostasis, 222–224
  Calcium antagonists
    effects of, in uterine atony, 121
    risks and benefits of, 171
  Calcium channel blockers
    for antihypertensive therapy in preeclampsia, 510
    interaction of, with inhalational anesthetics, 299
  Canadian Multicenter Postterm Pregnancy Trial, on management of postdate pregnancy, 304
  Carbamazepine, in pregnancy, risk of fetal abnormalities, 459–460
  Carprofen (15-methyl prostaglandin F2β), for treating postpartum hemorrhage, 116
  Cardiac adjustment, in diabetic parturients, 337
  Cardiac arrhythmias, management of, during pregnancy, 170–172
  Cardiac delivery, description of, 180
  Cardiac dysfunction, in postpartum hemorrhage, 125
  Cardiac output
    change in, during pregnancy, 89
    fetal, 2
    response to hypoxemia, 493
    maternal
      during gestation, 155–157, 505
      in the neonate, 7
  Cardiac surgery, during pregnancy, 166–167, 371
  Cardiac transplant, effect of, on pregnancy after, 197–198
  Cardiac valves
    diseases of, 175–179
    prosthetic, thromboembolism associated with, 371
  Cardioactive drugs, for conversion of fetal supraventricular tachycardia, 29
  Cardiomyopathy
    hypertrophic, 172–175
    peripartum, 511–512
    termination of pregnancy in, 166
    in systemic lupus erythematosus, 268
  Cardiopulmonary arrest, 507–508
  Cardiopulmonary bypass (CPB) surgery
    in anamniotic fluid embolism, for treating postpartum shock, 359
    in maternal cardiac arrest, 168
    during pregnancy, 166, 192
Cesarean delivery
anesthesia for
in alcoholic parturients, 412–413
in cocaine use, 422
for diabetic parturients, 343
in drug abuse, 410
in hypertension
of a breech-presenting fetus, 75
in cardiovascular disease, risks of, 162
elective, for hypertrophic
cardiomyopathy patients, 173
emergency, categories of, 498
in fetal distress, 491
in human immunodeficiency virus
infection, 392, 441–442
with hysterectomy, in placenta accreta, 103
indications for, 28
in malignant hyperthermia, 250
in mitral valve prolapse, 177
in multiple gestations, 83–84
for narcotics abusers, 415–416
in nonreassuring fetal testing, 293
for obese patients, 57–63
perimortem, 242–243
in cardiac arrest, 167
after failure of resuscitation, 508
in peripartum cardiomyopathy, 175
in renal disease patients, anemia for, 213–214
versus vaginal delivery, in myocardial infarction in pregnancy, 192
in vasa previa, 101
venous air embolism associated with, 360–361
Chemical analysis, to identify abused drugs, 404
Chromatography, for identifying illegal drugs, 404
Chromosomes/chromosomal abnormalities, 23
X, factor VIII on, 320
See also Congenital abnormalities/anomalies; Down syndrome; Trisomy; Turner’s syndrome
Chvostek’s sign, in hypoparathyroidism, 223–224
Cigarette smoking. See Smoking.
Circadian rhythm, in fetal breathing activity, 5–6
Circulation access to, during fetal surgery, 41
in pregnancy, 88–89
responses to untreated hemorrhage, 124
Cirrhosis, liver, 477–478
Classification of asthma severity, 144
of burns, 511
Cobb, of scoliosis, 234
of diabetes in pregnancy, 339–340
of emergency cesarean sections, 498
of hemorrhage in a parturient, 87, 113–114
of hormone effects, 217
of hypertension in pregnancy, 279–280
of preeclampsia, 280
of von Willenbrand’s disease, 313
Clinical course of aortic stenosis, 179
of peripartum cardiomyopathy, 174
Clinical presentation of mitral stenosis, 181
of mitral valve prolapse, 176
of pheochromocytoma, 196
of preeclampsia, 281–282
See also Symptoms
Clonazepam, birth defects associated with, 458
Clozapine, side effect of, agranulocytosis, 458
Index

Coagulation changes in pregnancy, 506 and obesity, 55
Coagulation cascade dysfunction in hepatic disease, 465
Contraindications (Continued)
in pregnancy, 124
therapeutic anticoagulation as, 327
to spinal-epidural anesthesia, in
anticoagulated patients, 376–377
to succinylcholine use, for renal disease
patients, 213
Convulsions
in amniotic fluid embolism, 357–358
eclamptic, differentiating from amniotic
fluid embolism, 358
in preeclampsia, managing, 287–288
from toxic reaction to anesthetics,
differentiating from amniotic fluid
embolism, 358
Coomb’s test, for antibody detection, 275
Cordocentesis
to assess fetal oxygenation and acid-base
status, 494
to diagnose hemoglobin Bart’s hydrops
fetalis, 261
uses and risks of, 25
Coronary vasculitis, in rheumatoid arthritis,
265
Cortical vein thrombosis, 139–140
Corticosteroids
for antibody-dependent cell-mediated
cytotoxicity (ADCC) treatment, 275
association with cleft lip, 270
for dermatomyositis/polymyositis, 271
for the mother, to promote fetal lung
maturity, 241
replacement of, for panhypopituitarism
patients during pregnancy, 230
Cortisol
functions of, 224
neonatal withdrawal, due to maternal
Cushing’s syndrome, 225
Coumadin, for managing
thromboembolism in pregnancy, 351
Counseling
after diagnosis of hemoglobin Bart’s
hydrops fetalis, 261
preconceptual, for women with
cardiovascular disease, 159
Creatinine, clearance of, during pregnancy,
207–208
Crista dividens, control of oxygenated
blood flow by, 1–2
Critical care, management of, in
pregnancy, 506–507
Critical illness, in pregnancy, 507–511
Cromolyn sodium, for managing asthma
during pregnancy, 145
Cross-dependent drugs, 403–404
alcohol with central nervous system
depressants, 410
Cross-tolerance, alcohol with marijuana,
416
Cryoprecipitate
for renal disease patients on dialysis,
before delivery, 212
for treating von Willenbrand’s disease,
Types 2 and 3, 313
Curettage, to empty the uterus, in
management of postpartum
hemorrhage, 117
Cushing’s disease, 225–226
Cyclooxygenase inhibitors, effects of, on
uterine contraction, 299
Cycloserine, contraindication to use in
pregnancy, 398
Cyclosporin, association with spontaneous
abortion and preterm delivery, 270
Cystic fibrosis (CF), effects of, on
pregnancy, 150
Cystitis, treating in pregnancy, 210
Cytomegalovirus (CMV), 389–390
D
Dantrolene, for treating malignant
hyperthermia, 245, 248–250
Dapsone, for treating idiopathic
thrombocytopenic purpura, 275
Decongestants, for managing asthma
during pregnancy, 146
Deep venous thrombosis (DVT)
managing with heparin, 372
in pregnancy, 347
risks of, 369–370
Defibrillation, protection of the fetus in,
167
Delayed air embolism, 362
Delivery
effect of
on myocardial ischemia and
congestive heart failure, 192
on preeclampsia, 285
management of, 57–60
for diabetic gravidae, 341
Demography
of cardiovascular disease in pregnancy,
155
of drug abuse, 405
Dependence, on drugs, defined, 403–404
Depression
incidence of, by gender, 447
major, 447–448
paternal, after perinatal loss, 451
Dermatomyositis (DM), 271–272
Desensitization, to penicillin, 397
Desflurane, comparison with isoflurane, in
general anesthesia, 63
Desmopressin, for managing von
Willenbrand’s disease, Type 1, 312–313
Desmopressin response test, for diagnosing
diabetes insipidus, 229
Detoxification, prior to pregnancy and
early in pregnancy, 412, 414
Diabetes in Early Pregnancy project,
National Institute of Child Health
and Human Development
(NICHD), 338
Diabetes insipidus, management of, in
pregnancy, 229
Diabetes mellitus
association with obesity, 56
risk of intrauterine growth restriction in,
518
risk of myocardial infarction in
pregnancy in, 190
type 1, effect on fetal death rate, 520
uncontrolled, effects on metabolism, 336
in women with cystic fibrosis, 150
Diabetic ketoacidosis (DKA), 334–336
risk of fetal death in, 520
Diabetic parturient, 333–345. See also
Diabetes mellitus
Diagnosis
of abruptio placentae, 90–91
of amniotic fluid embolism, 357–358
of antiphospholipid syndrome, 268–269
depression, criteria for, 447–448
of diabetic ketoacidosis, 336
of fetal congenital abnormalities, 27–28
of fetal death, 516
accompanied by disseminated
intravascular coagulation, 524
of fetal distress, 493–495
of hemoglobin Bart’s hydrops fetalis, 261
of herpes simplex virus infection,
393–394
in hyperthyroidism in pregnancy, 218
of ischemic heart disease, in pregnant
women, 191
of placenta accreta, placenta increta and
placenta percreta, 102
of placenta previa, 95–96
of polymyositis, 271
of preeclampsia, 279
prenatal, of fetal disorders, 23–26
of preterm labor, 292–293
of pseudocyesis, 452
of pulmonary embolism, 349–350
of α-thalassemia, 258–259
of twin gestation, 80
of uterine rupture, 104–105
of vasa previa, 100–101
of venous air embolism, 362
of viral hepatitis, 390
Diagnostic peritoneal lavage (DPL), in
trauma, 239, 241–242
Dialysis, renal, rate of spontaneous
abortion in, 211
Diazepam, for convulsions in
preeclampsia, 287–288
Dichorionic-diamniotic placentation, 77
Index

Diet
  effects of, on preeclampsia, 285
  restrictions on, in acute renal failure, 209

Differential diagnosis
  of amniotic fluid embolism, 358
  in cardiopulmonary arrest, pregnancy-related, 167–168
  of hypotension, 124–125
  of malignant hyperthermia, 443
  of placental abruption, 91
  of placenta previa, 96
  of postpartum fever, in malignant hyperthermia susceptible patients, 250–251
  of preecclampsia, 281
  of pulmonary embolism, 370

Digoxin, for treating atrial tachycardia, 168

Diltiazem, congenital anomalies produced by, 171

Dilutional coagulopathy, in placental abruption, 94

Diphenhydramine, teratogenicity of, 458

Diphosphoglycerate (2,3-DPG), effect of, on oxygen binding by hemoglobin, 333–334

Disseminated intravascular coagulation (DIC), 318–319
  in amniotic fluid embolism, 356–357
  and anesthesia in placental abruption, 242
  arterial embolization for managing, 117–118
  in fetal death, 524
  in HELLP syndrome, potential results of, 317
  in placenta accreta, decision about
epidural catheter removal in, 104
  in placental abruption, 93–94, 240, 518
  in postpartum hemorrhage, 128
  as a predictor of fetal mortality, 238
  Diuretics, effects of, on the fetus, 283
  Dizygotic twinning, risk factors for, 77
  DNA studies, in diagnosis of
  α-thalassemia-1
  of parents, 259
  of the fetus, 261
  Doppler ultrasound velocimetry, for fetal assessment, 9
  Double setup, for examination in placenta previa, 97–98
  Down syndrome
  history of identification, 23
  maternal serum screening to detect, 27
  testing to identify, 10
  Doxycycline, for treating Lyme disease, 395

Drug abuse
  addiction to barbiturates, in pregnancy, 413
  association of
  with depressive symptoms, 447
  with fetal death, 515, 522
  with hepatic disease, 518–519
  detecting, 404
  maternal, fetal distress in, 407
  Drug use studies, limitations of, 405
  Dubin-Johnson syndrome, 482
  Duchenne’s muscular dystrophy, transmission pattern, 137
  Ductal constriction, due to indomethacin administration, 299
  Ductus arteriosus
  closure of, 7
  Ductus venous, closure of, 7
  Dührssen’s incisions, to facilitate delivery in fetal head entrapment, 70
  Dyspnea, in pregnancy, reasons for, 143
  Dysrhythmia, cardiac, monitoring for, in
  hypoparathyroidism, 224
  Dystocia, and fetal weight, 69–70
  Dystrophin, analysis of, to diagnose muscular dystrophy, 137
  Eating disorders, managing in pregnancy, 449
  Ebstein’s anomaly
  effects of, in pregnancy, 185
  risk for, in lithium exposure of the fetus, 459
  Echocardiographic criteria, defining peripartum cardiomyopathy, 173
  Echocardiography
  for cardiac monitoring in placental abruption, 93
  transesophageal in amniotic fluid embolism, 358
  in Marfan syndrome, 194
  Echogenic bowel, fetal, anomalies associated with, 260–261
  Eclampsia, 279–290
  morbidity and mortality in, 510
  Eclampsia Trial Collaborative Group, on risk of seizures, studies of drugs used in preeclampsia, 510
  Edrophonium, for evaluating crises in
  malignancy, 124–125
  in cardiopulmonary arrest, pregnancy-related
  of trauma to the pregnant woman, 238
  Epidemiology
  of adolescent pregnancy, 45–46
  of adult respiratory distress syndrome, 147
  of asthma in pregnancy, 143
  of fetal death, 515
  of smoking, 149
  of α-thalassemia, 254
  for cocaine users in labor, 422
  of myocardial infarction patients, 193
  contraindication to, in placental abruption, 92
  for delivery of a breech-presenting fetus by cesarean section, 75
  effect of
  on fetal heart rate, 18
  on maternal temperature, 7
  for external cephalic version, 73
  for fetal head entrapment delivery, 75
  for hepatic disease patients, 468–469
  Electrolytes, urinary, levels of and fetal renal function, 33–34
  Embolectomy, pulmonary, criteria for use of, 352
  Embolism, 347–367
  amniotic fluid, 511
  Embryopathy, from warfarin use, 183
  Encephalopathy, in hepatic disease, 479
  Endocarditis, association of with aortic stenosis, 180
  with mitral regurgitation, 177
  with mitral valve prolapse, 176
  Endocrine disorders, 217–231
  association with fetal death, 520–522
  changes with obesity, 55
  See also Hormones
  End-stage renal disease (ESRD), progression to, in pregnancy, 209
  Environmental exposures, and fetal death, 522–523
  Enzyme-linked immunosorbent assay (ELISA)
  for diagnosing Lyme disease, 395
  for diagnosing toxoplasmosis, 397
  Enzyme-mediated immunotechnique (EMIT), for identifying illegal drugs, 404
  Ephedrine, for hypotension in β-agonist therapy, 298
  maternal, 495–496
  in mitral regurgitation patients, 178
  in regional anesthesia, 165
  Electrolytes, urinary, levels of and fetal renal function, 33–34
  Embolectomy, pulmonary, criteria for use of, 352
  Embolism, 347–367
  amniotic fluid, 511
  Embryopathy, from warfarin use, 183
  Encephalopathy, in hepatic disease, 479
  Endocarditis, association of with aortic stenosis, 180
  with mitral regurgitation, 177
  with mitral valve prolapse, 176
  Endocrine disorders, 217–231
  association with fetal death, 520–522
  changes with obesity, 55
  See also Hormones
  End-stage renal disease (ESRD), progression to, in pregnancy, 209
  Environmental exposures, and fetal death, 522–523
  Enzyme-linked immunosorbent assay (ELISA)
  for diagnosing Lyme disease, 395
  for diagnosing toxoplasmosis, 397
  Enzyme-mediated immunotechnique (EMIT), for identifying illegal drugs, 404
  Ephedrine, for hypotension in β-agonist therapy, 298
  maternal, 495–496
  in mitral regurgitation patients, 178
  in regional anesthesia, 165
  Epidemiology
  of adolescent pregnancy, 45–46
  of adult respiratory distress syndrome, 147
  of asthma in pregnancy, 143
  of fetal death, 515
  of smoking, 149
  of α-thalassemia, 254
  of trauma to the pregnant woman, 238
  Epidural analgesia/anesthesia
  advantages of, for diabetic parturients, 343
  for cardiovascular disease patients, 164–165
  for cocaine users in labor, 422
  continuous
  for mitral valve prolapse patients, 177
  for myocardial infarction patients, 193
  contraindication to, in placental abruption, 92
  for delivery of a breech-presenting fetus by cesarean section, 75
  effect of
  on fetal heart rate, 18
  on maternal temperature, 7
  for external cephalic version, 73
  for fetal head entrapment delivery, 75
  for hepatic disease patients, 468–469
Epidural analgesia/anesthesia (Continued)
in hip surgery, incidence of deep venous thrombosis and pulmonary embolism, 353
in hypertrophic cardiomyopathy, 173
for labor
for drug abusers, 409–410
in pheochromocytoma, 227–228
for mitral regurgitation patients, 178
for morbidly obese patients, 61
in multiple sclerosis, 134–135
neurologic dysfunction from hemorrhagic complications in, 375
new-onset back pain following use of, 233
for obese patients, 58–59
for obstetrical patients with cystic fibrosis, 150
for opiate abusers, 415–416
for placenta accreta management, 104
planning for, in preterm labor, 295–296
for placenta accreta management, 104
for patients undergoing hemodialysis, 213
risks of
at delivery in multiple gestations, 83
after lumbar spine surgery, 235
in spinal cord injuries, 138
for the teenaged obstetrical patient, 48
in thoracic surgery, 63–64
Epinephrine
effects on heart rate, 5
in management of anesthesia
for hypertrophic cardiomyopathy patients, 173
after treatment for fetal arrhythmias, 29
release of, from the adrenal medulla, 224
in renal disease, contraindication to use of, 213
Episiotomy, likelihood of, and fetal macrosomia, 305–306
Epoprostenol, for managing primary pulmonary hypertension, 189
Ergot alkaloids
contraindication to
in malignant hyperthermia sensitive patients, 247
during pregnancy, 133–134
effects of, on postpartum hemorrhage, 115–117
Erythroblastosis fetalis, 253
intervention in, history of, 33
Erythrocytes
hemoglobin of, affinity for oxygen in the fetus, 4
increase in the mass of, during pregnancy, 157
salvage of, in placenta previa, 100
Erythropoiesis, hemoglobins involved in, 255–256
Erythropoietin, for managing an anemic patient with placenta previa, 98–99
Esmolol, effect of
on fetal heart rate, 171
in thyroid storm, 220
Esophageal varices, 479
Estrogen, association with thrombosis, 324
Ethambutol, for treating tuberculosis, 398
Ethanol
effect on pregnancy and delivery, 410–413
as a tocolytic agent, 293
See also Alcohol
Ethionamide, contraindication to use in pregnancy, 398
Ethnicity, and teenaged birthrate, 45
Etiology
of acute renal failure, 208–209
of amniotic fluid embolism, 355–356
of ankylosing spondylitis, 273
of antiphospholipid syndrome, 268–269
of cholestastic liver disease, 481–482
of fetal death, 516–517
of hypothyroidism, 221
of idiopathic thrombocytopenic purpura, 274
of mitral regurgitation, 177–178
of myasthenia gravis, 269–271
of obstetric hemorrhage, 87
of postpartum hemorrhage, 113
of preterm labor, 291–292
of scleroderma, 272
of systemic lupus erythematosus, 267
of thromboembolic disease, 347–348
of venous air embolism, 361
Etomideate, for induction of general anesthesia, 500
in a morbidly obese parturient, 62
in placental abruption, 92
in placenta previa, 98
European Malignant Hyperthermia Group, protocol for contracture testing, 245
Euvolemia, maintaining, in hypertrophic cardiomyopathy patients, 173–175
Evaluation
of drug use, in prenatal care, 408–409
in placental abruption, 92
See also Assessment; Diagnosis
Evans myopathy, 246–247
Expiratory reserve volume (ERV), reduction of, and obesity, 54
External cephalic version (ECV) anesthesia for, 73
for delivering the second of twins, 80–81
at term, for transverse or oblique presentations, 71–72
Extracorporeal membrane oxygenation (ECMO), for managing the fetus with lung masses and diaphragmatic hernia, 35–36
Ex utero intrapartum treatment (EXIT) procedure, for managing congenital abnormalities, 35–37, 39

F
Face presentation, 75–76
Factor deficiencies, 319–321
Factor V Leiden (FVL) association with thromboembolism in pregnancy, 370
resistance to activated protein C due to, 325
as a risk factor for pregnancy-related thrombosis, 327, 521–522
Famciclovir, for herpes simplex virus infection, 393
Fascioscapulohumeral dystrophy, limb girdle dystrophy, 137
Febrile parturient, 433–445
Federal Drug Administration (FDA), drug classification by, 506
Fenoldopam, in placental abruption with acute renal failure, 93
Fentanyl
as an alternative to monoamine oxidase inhibitors, 458
for analgesia in labor
with a breech presentation, 74
effects on neonatal respiration, 188–189
effects on the fetus, 165
in back pain patients, 236
in von Willenbrand’s disease patients, 314
Fertility, and renal disease, 210
Fetal abnormalities, nonviable, anesthetic implications for the patient, 30
Fetal alcohol syndrome (FAS), 407, 412, 481
Fetal alcohol syndrome (FAS), drug defined, 491
in maternal drug abuse, 407
Fetal head entrapment, anesthesia in the presence of, 74–75
Fetal heart rate (FHR), effect of esmolol on, 171
monitoring, in maternal cardiac surgery, 167
patterns in, 13–19
Index

Fetal hydrops. See Hydrops fetalis
Fetal loss/death
association of
with anamniotic fluid embolism, 355
with anticardiolipin antibodies, 324–325
with cocaine use, 420
with diabetic ketoacidosis, 334–336
with narcotic use, 414
with protein C deficiency, 326
in factor V Leiden carriers, 325
intrauterine, 515–528
after monitoring diabetic parturients for fetal well-being, 341
See also Abortion; Intrauterine fetal demise; Mortality, fetal
Fetus
activity of, maternal assessment of, 10
anesthesia for, in fetal interventions, 39–41
effects on
of anesthetics, 296
of antiarrhythmic drugs, 168–172
cocaine, 420
of hepatic dysfunction, 466–467
of marijuana, 416
of maternal alcohol abuse, 411
of maternal fever, 436
of maternal hemorrhage, 88
of maternal substance abuse, 407
of narcotic abuse, 414
of tobacco smoking, 425
half-life of indomethacin in, 299
management of, in hypertensive disorders, 471–472
risk to, of malignant hyperthermia, 246
Fever, pathogenesis of, 433
Fibrinogen, as an indicator of disseminated intravascular coagulation, 94
Fibrin split products (FSP), effects on levels of, of placental abruption, 93–94
Fibronectin, fetal, in cervicovaginal secretions, and premature delivery, 292
Fick principle, using to calculate oxygenation levels, 4
Filters, inferior vena caval, to prevent pulmonary embolization from deep venous thrombosis, 352
Finnegan scale, for rating symptoms of neonatal abstinence, 414
Fish oils, effects of, on preeclampsia, 285
Floppy infant syndrome, association with benzo diazepines, 459
Fluid injection, association of, with amniotic fluid embolism, 356
Fluid management, in renal disease patients, 214
Fluorescent in situ hybridization (FISH), for identifying chromosomal aneuploidies, 27
Fluoxetine (Prozac), effects of, on the fetus, 454–455
Footing breech, risk associated with, 69–70
Foramen ovale, closure of, 7
Forceps delivery
anesthesia for, perineal, 343
in myocardial infarction in pregnancy, 193
Fresh-frozen plasma (FFP), clotting factors of, in use postpartum hemorrhage, 127
Fulminant hepatic failure, 480–481
Functional residual capacity (FRC), reduction of
and obesity, 54
in pregnancy, 88
G
Gas exchange
fetal, 1
placental, and fetal oxygenation, 3–4
Gastrointestinal changes
in obesity, 54–56
in trauma, 238
General anesthesia
for cesarean delivery
of cocaine-abusing parturients, 422
of diabetic parturients, 343
of morbidly obese patients, 61–63
of multiple gestations, 83
for drug abusers, 410
in Eisenmenger’s syndrome patients, 188
for the febrile parturient, 436–437
in hip replacement, incidence of thrombosis and pulmonary embolism, 353
in hypertrophic cardiomyopathy, 173
in intrapartum fetal distress, 499–500
in management of placenta accreta, 103–104
in management of placenta previa, 97–98
morbidity and mortality associated with multiple gestations, 83
in pheochromocytoma, 228
Genetic counseling, in hemoglobin Bart’s hydrops fetalis, 259–260
Genetic factors, in preeclampsia, 279
Genetic risk, for placental abruption, 90
Genetics, of malignant hyperthermia, 245
Genetic testing, for cystic fibrosis patients, 150
Genital infections, association with pretterm delivery, 292
Genital tract trauma
postpartum hemorrhage due to, 113, 122–123
repair of, after resuscitation, 129
Genitourinary changes, in pregnancy, effect of trauma on, 237
Genome project, and identification of fetal disorders, 23–26
Genotype, in hemoglobin Bart’s hydrops fetalis, 253
Geographic patterns, of drug choice, 405
Gestation
higher-order, 81–84
multiple, association with fetal deaths, 8
Gestational diabetes, 340–341
in twinning, 78
Gestational hypertension, 196
Glanzmann’s thrombasthenia, 315
Glomerular filtration rate (GFR), increase in, during pregnancy, 207–208, 506
Glucocorticoids
for managing HELLP syndrome, 316–317
for managing idiopathic thrombocytopenic purpura, 274
replacement therapy, for perioperative thyroid storm patients, 220
Glucose, blood levels of, and breathing fetal movement, 6
Glucosuria, normal, in pregnancy, 207
Glycogenolysis, in response to fetal hypoxemia, 493
Glycoproteins, platelet membrane autoantibodies to, in idiopathic thrombocytopenic purpura, 274
defects of, in Glanzmann’s thrombasthenia, 315
Goiter, fetal, from maternal lithium ingestion, 459
Gonorrhea infection, age-specific rates of, 47
Graves’s disease, maternal anesthesia management in, 29
causing neonatal disease, 218
fetal death associated with, 520–521
Great arteries, diseases of, 194–195
Grieving, in perinatal loss, 450–451
Growth restriction, fetal
in maternal congenital heart disease, 184
in maternal Eisenmenger’s syndrome, 187
in maternal primary pulmonary hypertension, 189
in maternal tobacco smoking, 425
in tetralogy of Fallot, 186
See also Intrauterine growth restriction Guidelines
for electroconvulsive therapy, 453
for transfusion, 125–126
See also American Society of Anesthesiologists, guidelines

539
Hair analysis, to identify nicotine and cocaine use, 404
Haloperidol, 458
Halothane, effects of, on the fetus, 41
Handicaps, severe, and multiple gestations, 82
HbH disease
defined, 253
genetic counseling in, 260
Headache, 133–134
Head injury, mortality from, 240
Head’s reflex, 8
Hearing loss, congenital, from cytomegalovirus infection, 390
Heart failure, association with hyperthyroidism in pregnancy, 218
Heart rate
change in, during pregnancy, 156
fetal, 4–5
monitoring of, 13–18
See also Bradycardia; Tachycardia
Hematocrit, high, in infants of diabetic mothers, 344
Hematologic disorders, 309–332
Hematoma, 139
Hemorrhagic shock, differentiating from amniotic fluid embolism, 358
Hemorrhagic disease of the newborn
in prematurity, 111–132
relationship with human immunodeficiency virus infection, 392
Hematomas
epidural
incidence of, 309
after regional anesthesia, 354, 376
genital tract, identifying and managing, 122–123
hepatic, 472
spinal, risk in aspirin ingestion, 377
spinal-epidural, 375–377
Hemodialysis, indications for, in acute renal failure, 209
Hemodynamic changes
monitoring of
in mitral stenosis, 182
in pregnancy, 506–507
in preeclampsia, 509
in pregnancy, 155–156, 505–507
Hemoglobin
A_K, glycemic control assessment in terms of, 333–334
electrophoretic analysis of, to diagnose β-globin chain abnormalities, 258
S, amino acid substitution in, 322
Hemoglobin Bart’s hydrops feticis syndrome, nonimmune hydrops feticis due to, 253–264
Hemoglobinopathies, 322–323
Hemolysis, fetal, from maternal autoimmune antibodies, 275
Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, 281, 316–318, 472–473
preeclampsia variant, 509
Hemolytic disease, fetal death in, 521
Hemolytic uremic syndrome (HUS), 318, 471
Hemophilia A (factor VIII deficiency), 319–320
Hemophilia B (Christmas disease), 320
Hemorrhage
and anesthetic management in placenta previa, 97–98
antepartum, 87–109
from anticoagulant therapy, in Eisenmenger’s syndrome, 187
avoiding, with cesarean delivery versus active labor, 295
fetal
intracranial, in alloimmune thrombocytopenia, 315
in warfarin therapy, 351
fetomaternal, and rhesus immunization, 240
in heparin therapy, 351
maternal risk of, 372
neonatal intraventricular, in vaginal breech delivery, 69–70
obstetric, mortality in, 309
postpartum, 111–112
in multifetal pregnancy, 80–81
in myotonic disorders, 136–137
in von Willenbrand’s disease, 313
uterine, effect of, on asthma control, 143–144
Hemorrhagic shock, differentiating from amniotic fluid embolism, 358
Hemostasis
postpartum, and uterine retraction, 112
primary, defined, 309–310
Heparin
actions of, on clotting, 350–351
for anticoagulation in asthma, 438–439
for antiphospholipid syndrome management, 520
benefits and risks of during pregnancy, 327, 369
in maternal cardiovascular disease, 161, 371–374
in peripartum cardiomyopathy, 175
thromboelastography to assess anticoagulation in therapy with, 378
use of, in pregnancy, 506
Heparin-induced extracorporeal LDL plasmapheresis (HELP), 392–393, 442–443, 474–477 toxic, from anesthetics for patients with liver disease, 468
Hepatorenal syndrome, 470
mortality in, 465
Hereditary disorders autosomal dominant
achondroplasia, 236
cogulopathies, 521–522
hypertrophic myopathy, 172–173
malignant hyperthermia, 245–252
Marfan syndrome, 194
osteogenesis imperfecta, 236
von Willenbrand’s disease, 312–314
autosomal recessive
Bernard-Soulier syndrome, 314–315
factor XI deficiency, 320–321
Glanzmann’s thrombasthenia, 315
hereditary hemorrhagic telangiectasia, 478
X-linked recessive
hemophilia A, 319–320
hemophilia B, 320–321
muscular dystrophies, 137
See also Chromosomes/chromosomal abnormalities; Congenital abnormalities/anomalies
Herpes simplex virus infection, 393–394, 438–439
Herpes zoster infection, defined, 399
Herring Breuer inflation reflex, 7–8
Hippocrates, description of pseudocyesis by, 452
History, medical, to determine susceptibility to malignant hyperthermia, 246
Hormones
association of, with panic disorders, 449
effects of, on fetal heart rate, 5
effects of, in postpartum depression, 448
effects on, of narcotic abuse in pregnancy, 413–414
response of, to hypoglycemia in pregnant diabetic women, 337
steroid therapy in asthma, effect on fetal well-being, 144
See also Endocrine disorders
Hughes syndrome. See Antiphospholipid antibody syndrome
Human immunodeficiency virus (HIV) infection, 441–442
in adolescents, 47
in drug users, 406, 419
in pregnancy, 391–393, 409
interaction of methadone with zidovudine, 415
Hydralazine
in labor, for mitral regurgitation patients, 177
for vasodilation in preeclampsia, 510
Hydration, preoperative, in electroconvulsive therapy, 454
Hydrocephalus
maternal, with shunt, 140
and risks in vaginal breech delivery, 70
Hydrocortisone
for managing Addison disease, 225
for managing pulmonary vasospasm and pulmonary edema, 359
Hydrops fetalis, 253–264
due to α-thalassemia, 323
association with fetal lung masses, 34–35
intervention in, history of, 33
nonimmune, 30
prognosis in, 34
Hyperadrenocorticism, 225–226
Hyperbilirubinemia, association with preterm labor, 467
Hypercalcemia, 222–223
Hypercapnia, maternal, fetal respiratory alkalosis due to, 6
Hyperextension, of the fetal neck, and syndromes of, 324–325
Hyperextension, of the fetal neck, and vaginal breech delivery, 70
Hyperglucagonemia, in diabetic pregnancies, 520
Hyperkalemia
causing diabetic ketoacidosis, 334–336
due to β-agonist use, 298
Hyperlipidemia, venous thromboembolism associated with, 348
Hyperinsulinemia, fetal, effect on oxygen demand, 334
Hyperkalemia
in renal disease, and anesthesia, 212
as a sign of malignant hyperthermia, during labor, 248
following the use of succinylcholine, 437
Hyperparathyroidism, 222–223
Hypertension/hypertensive disorders
association of with abruptio of the placenta, 92
with aneurysmal bleeding, 139
and body mass index, 54
categories of, in pregnancy, 509
chronic, 196
and obesity in pregnancy, 56
in Cushing’s disease, 225
in diabetic gravidas, 336
effect of, on asthma, 143–144
under general anesthesia, effects of cocaine on, 422
gestational, defined, 279
in pregnancy, 196–197
classification of, 470–472
pulmonary, association with pulmonary emboli, 349
as a relative contraindication of ketamine use, 63
in renal disease, effect on choice of anesthesia, 212
and risk of fetal death, 522
and risk of myocardial infarction, 190
systemic, from ergot alkaloids, 115–116
treatment of, effects on the mother, 284–285
See also Pulmonary hypertension
Hyperthermia, fetal, in methylenedioxymethamphetamine use, 424
Hyperthyroidism, 218–220
Hypertrophic cardiomyopathy (HOCM), 172–173
as a cause of fetal death in diabetic pregnancies, 520
Hyperventilation, maternal respiratory acidosis due to, 6
Hypoadrenocorticism, 224–225
Hypocalcemia
effect of, on myometrial contraction, 127
neonatal, due to maternal hyperparathyroidism, 223
Hypoglycemia, in diabetic parturients, 348
Idiopathic thrombocytopenic purpura
platelet destruction by autoantibodies in, 311–312
Immunoglobulins
anti-D, in fetomaternal hemorrhage, 240
in hepatitis A infection, 475–476
IgG
antiplatelet antibodies, risk to fetus for thrombocytopenia from, 275, 311
in Lyme disease, 395
in parvovirus B19 infection, 395
in toxoplasmosis, 397
IgM
in autoimmune hemolytic anemia, 275
in parvovirus B19 infection, 395, 397
in toxoplasmosis, 397
in peripartum cardiomyopathy, retrospective study, 175
in varicella, for perinatal exposure to varicella zoster, 399
Immunologic diseases, and risk of fetal death, 519–520
Impedance plethysmography, to detect venous thrombosis, 350
In pregnancy, 196–197
classification of, 470–472
pulmonary, association with pulmonary emboli, 349
as a relative contraindication of ketamine use, 63
in renal disease, effect on choice of anesthesia, 212
and risk of fetal death, 522
and risk of myocardial infarction, 190
systemic, from ergot alkaloids, 115–116
treatment of, effects on the mother, 284–285
See also Pulmonary hypertension
Hyperthermia, fetal, in methylenedioxymethamphetamine use, 424
Hyperthyroidism, 218–220
Hypertrophic cardiomyopathy (HOCM), 172–173
as a cause of fetal death in diabetic pregnancies, 520
Hyperventilation, maternal respiratory acidosis due to, 6
Hypoadrenocorticism, 224–225
Hypocalcemia
effect of, on myometrial contraction, 127
neonatal, due to maternal hyperparathyroidism, 223
Hypoglycemia, in diabetic parturients, 348
Idiopathic thrombocytopenic purpura
platelet destruction by autoantibodies in, 311–312
Immunoglobulins
anti-D, in fetomaternal hemorrhage, 240
in hepatitis A infection, 475–476
IgG
antiplatelet antibodies, risk to fetus for thrombocytopenia from, 275, 311
in Lyme disease, 395
in parvovirus B19 infection, 395
in toxoplasmosis, 397
IgM
in autoimmune hemolytic anemia, 275
in parvovirus B19 infection, 395, 397
in toxoplasmosis, 397
in peripartum cardiomyopathy, retrospective study, 175
in varicella, for perinatal exposure to varicella zoster, 399
Immunologic diseases, and risk of fetal death, 519–520
Impedance plethysmography, to detect venous thrombosis, 350

I
Iatrogenic conditions, in intractable hypotension, 125
Idiopathic hypertrophic subaortic stenosis (IHSS). See Hypertrophic cardiomyopathy
Idiopathic thrombocytopenic purpura (ITP), 274–275
platelet destruction by autoantibodies in, 311–312
Immunoglobulins
anti-D, in fetomaternal hemorrhage, 240
in hepatitis A infection, 475–476
IgG
antiplatelet antibodies, risk to fetus for thrombocytopenia from, 275, 311
in Lyme disease, 395
in parvovirus B19 infection, 395
in toxoplasmosis, 397
IgM
in autoimmune hemolytic anemia, 275
in parvovirus B19 infection, 395, 397
in toxoplasmosis, 397
in peripartum cardiomyopathy, retrospective study, 175
in varicella, for perinatal exposure to varicella zoster, 399
Immunologic diseases, and risk of fetal death, 519–520
Impedance plethysmography, to detect venous thrombosis, 350

I
Iatrogenic conditions, in intractable hypotension, 125
Idiopathic hypertrophic subaortic stenosis (IHSS). See Hypertrophic cardiomyopathy
Idiopathic thrombocytopenic purpura (ITP), 274–275
platelet destruction by autoantibodies in, 311–312
Immunoglobulins
anti-D, in fetomaternal hemorrhage, 240
in hepatitis A infection, 475–476
IgG
antiplatelet antibodies, risk to fetus for thrombocytopenia from, 275, 311
in Lyme disease, 395
in parvovirus B19 infection, 395
in toxoplasmosis, 397
IgM
in autoimmune hemolytic anemia, 275
in parvovirus B19 infection, 395, 397
in toxoplasmosis, 397
in peripartum cardiomyopathy, retrospective study, 175
in varicella, for perinatal exposure to varicella zoster, 399
Immunologic diseases, and risk of fetal death, 519–520
Impedance plethysmography, to detect venous thrombosis, 350
Implantable cardioverter-defibrillator (ICD), preconception implantation of, 172

Incidence of amniotic fluid embolism, 355 of cocaine use by pregnant women, 418 of deep venous thrombosis, during pregnancy, 347–354 or drug abuse in pregnancy, reported, 404–405 of ethanol abuse, maternal, 411 of fetal distress, 491–492 of hepatitis A virus infection in pregnancy, 475 of herpes zoster virus infection in pregnancy, 399 of placental abruption, 90 of postdate pregnancy, 303 of postpartum hemorrhage, 112 of syphilis, 396–397 of venous air embolism, 360–361

Indications for amniocentesis, 8 for anticoagulant therapy in pregnancy, 369–371 for Cesarean delivery, 28 maternal, for delivery in HELLP syndrome, 316–317 for postpartum blood transfusion, 120 for postpartum hysterectomy, 120

Indirect fluorescent antibody (IFA) test for diagnosing toxoplasmosis, 397 for diagnosing Lyme disease, 395

Indomethacin contraindications to use of, in trauma to the pregnant woman, 242 inhibition of prostaglandin synthesis by, 299

Induction agents, in fetal distress, 500–501 Infarction, hepatic, mortality in, 472

Infection infective endocarditis in pregnancy, 161–162 intraaortic, treating in pregnancy, 387 maternal and adult respiratory distress syndrome, 147–148 as a cause of fetal death, 517 incidence of, in labor, 435 not specific to pregnancy, 439–443 specific to pregnancy, 437–439 with twins delivered by cesarean section, 81

Infectious diseases, 381–402 herpes simplex virus, 438–439 renal, 210 risk of transmission in blood transfusion, 126

See also Hepatitis; Human immunodeficiency virus Infiltration anesthesia, in morbidly obese patients, 61 Inhalation agents, effects of, for patients with renal disease, 212 Inhalation injuries, in burn patients, 511 Inotropic agents, for peripartum cardiomyopathy management, 175 Insulin postpartum requirement for, by diabetic mothers, 342 therapy with, for diabetic parturients, 338

Intensive therapy unit (ITU), admission to, for postdelivery care for preeclamptics, 288–289 Interferon-α, therapy for hepatitis B, C, and D, 390, 476 Interferon-β, for managing multiple sclerosis, 134 Internal podalic version, in breech extraction of a second twin, 81 Interventions, in placenta accreta, nonsurgical, 103 Intoxication, from methylenedioxy-methamphetamine use, 424 Intracardiac shunts, management of, 184–185 Intracranial bleeding, fetal, with warfarin use, 183 Intrahepatic cholestasis of pregnancy (ICP), 481–482


Intestinal dysfunction, 474–475

Intubation under elective conditions, to assure control of the airway, 124 fiberoptic, before induction of general anesthesia, 62 of morbidly obese patients, difficulty with, 62 positioning a patient for, prior to cesarean surgery, 60–61 of preeclamptic patients, difficulty with, 88

In utero resuscitation, 496

In utero transfusion, in hemoglobin Bart’s hydrops fetalis, 262

In vitro contracture test (IVCT), for malignant hyperthermia diagnosis, 245–246

Ionizing radiation, exposure to, from diagnostic procedures, 157

Ion trapping, of anesthetics in the fetus, 296

Iron deficiency anemia, 321–322 laboratory diagnosis of, in pregnant women, 258

Isoflurane, inorganic fluoride levels in serum after anesthesia with, 63

Isoniazid, for tuberculosis treatment, 398

Isoveolemic hemodilution, in postpartum hemorrhage management, 126

K

Ketamine for analgesia in labor, in von Willenbrand’s disease patients, 314 for induction of general anesthesia, 500 in a morbidly obese parturient, 62 in placental abruption, 92 in placenta previa, 98

Ketoacidosis, diabetic, 334–336

Kidney, excretion of bicarbonate by, in compensation for reduced CO₂ in pregnancy, 143

Kleihauser-Betke test, for fetomaternal hemorrhage in RhD-negative patients, 240

Klinefelter syndrome, chromosome distribution in, 23

L

Labetalol, for managing pheochromocytoma in pregnancy, 227

Labetalol, for antihypertensive therapy in preeclampsia, 510
Labor analgesia during
for an expectant vaginal breech delivery, 73–74
in multiple gestations, 82–83
in renal disease, 213
chorioamnionitis presenting during, 438
management of, 57–60
monitoring for malignant hyperthermia, 248
in patients with asthma, 146
stage of
fourth, 112
third, active management in, 122
third, physiology of, 112
See also Premature labor; Preterm labor
Laboratory assessment, of postpartum hemorrhage, 128
Labor induction
indications for
in obese women, 57–60
in postdate pregnancy, 303–304
means of, in postdate pregnancy, 304
practice in postdate pregnancy, 305
Lacerations, postpartum hemorrhage due to, 113, 122–123
β-Lactams, for pneumonia during pregnancy, 148
Lactate dehydrogenase (LDH), for monitoring hemolytic uremic, and thrombotic thrombocytopenic purpura, 281
Laminecetomy, decompressive, in epidural hematoma formation, 376
Laparoscopy, in cholecystectomy, 483
Laparotomy, exploratory, for assessing trauma to the pregnant woman, 241–242
Laser occlusion, of communicating vessels, in twin-twin transfusion syndrome, 79
Lecithin/sphingomyelin ratio (L/S), assessing lung maturity by measuring, 10
Left ventricular hypertrophy (LVH) and morbid obesity, 54
in renal disease, effect on choice of anesthesia, 212
Lidocaine
effect of, on the preterm fetus, 296
for managing ventricular arrhythmias, 171
Life expectancy, in aortic stenosis, severe, 179
Life support protocol, advanced cardiac, 167
Limb reduction, in hemoglobin Bart’s hydrops fetalis, 261
Listeria monocytogenes, 394, 517
Listeriosis
as a cause of fetal death, 517
treating in pregnancy, 388
Lithium, use in pregnancy, 459
Liver cell adenoma, maternal and fetal mortality associated with, 478
 Lobectomy, for managing hydrops fetalis, 35
“Loss of resistance with air”, in epidural anesthesia, venous air embolism due to, 363
Low back pain (BLP), 233
Low birth weight (LBW) births, incidence of, 46
in placental abruption, 90
Low-dose heparin, prophylactic, and risk of spinal hematomas in epidural or spinal anesthesia, 375–376
Low-dose heparin, prophylactic, in risk of thromboembolic disease, 372
Low-dose methadone maintenance, in pregnancy, 414
Low molecular weight heparin (LMWH) in Eisenmenger’s syndrome, management in the perinatal period, 188
prophylaxis with, risk of spinal hematoma in, 376
risks of, during pregnancy, 183, 351
use of, 369, 373–374
Lumbar disc herniation, 234
Lumbar surgery, prevalence of, 235
Lung, fetal
assessment of the maturity of, 10
masses in, 34–35
Lung elastic properties, infant, effect of tobacco smoking on, 425
Lung maturity testing, for infants of diabetic mothers, 341
Lung-to-head ratio (LHR), and prognosis in congenital diaphragmatic hernia, 35
Lupus anticoagulant (LAC) association with hypercoagulation, 324–325
association with pregnancy loss, 268
See also Antiphospholipid antibody syndrome; Systemic lupus erythematosus
Lyne disease, 394–395
association with fetal death, 517
M
Macrolide antibiotics, for pneumonia during pregnancy, 148
Macrosomia
in diabetic parturients, 339, 520
in postdate pregnancy, 305–306
Magnesium, serum levels of, and muscle relaxants, 212
Magnesium sulfate
contraindication to, in trauma to the pregnant woman, 242
for control of seizures, 288
effect of
on preeclampsia, 286, 510
on pregnant patients, 39
on uterine relaxation, 121
for pheochromocytoma management, 228
for preterm labor management, 293, 298–299
Magnetic resonance angiography (MRA), for diagnosis of pulmonary embolism, 350
Magnetic resonance imaging (MRI), for diagnosis of deep venous thrombosis, 370
of epidural hematomas, 376
of fetal disorders, 25
of pheochromocytoma, 226
of placenta accreta, 121
of placenta previa, 96
Magnetic resonance imaging (MRI), for diagnosis of sacroiliac dysfunction versus lumbar disk herniation, 234
Maintenance therapy, after narcotic detoxification, 413
Malaria, treating in pregnancy, 388
Malignant hyperthermia (MH), 137, 245–252, 443
Malignant Hyperthermia Association of the United States (MHAUS), treatment recommended by, 249
Mallampati score, correlation with weight gain in pregnancy, 88
Malpresentation, 67–77
Management intrapartum, of twin gestation, 80–81
of peripartum cardiomyopathy, 174–175
Manipulation, intrauterine fetal, 33–44
March of Dimes Multicenter Prematurity Prevention Trial, 292
Marfan syndrome (MFS), 194
mitral valve prolapse associated with, 176
risks of pregnancy in, 166
Marginal sinus abruption, 89–90
Marijuana, 416–417
Markers, biochemical, of preterm birth, 291–292
Masseter muscle rigidity (MMR), association with malignant hyperthermia, 247
Maternal mirror syndrome, 261–262
in hydrops fetalis, 34
Mean cell volume (MCV), screening for thalassemias using, 256–257
Mechanical changes, respiratory, and obesity, 54
Mechanical valve prostheses, 182–183
Meconium, composition of, and amniotic fluid embolism, 356–357
Meconium testing, to identify drug exposure, 404
Medical management
of aortic insufficiency, 178
of aortic stenosis, 179–180
of cardiovascular disease in pregnancy, 160
of Eisenmenger’s syndrome, 187
of heart transplant patients, 197
of hypertension, 283–284
of idiopathic thrombocytopenic purpura, 274–275
of mitral regurgitation, 177
of mitral stenosis, 181
of myocardial infarction in pregnancy, 191–192
of pheochromocytoma, 196–197
of postpartum hemorrhage, 117
of smoking in pregnancy, 149
of tetralogy of Fallot, 185–186
Medications
adjusting dosages of, in pregnancy, 434
for ankylosing spondylitis, 273
antiepileptic, teratogenic effect of, 135
for asthma management during pregnancy, 145–146
cardiac, effects on the mother and fetus, 169
congenital malformations and fetal loss
associated with, 523
diuretics, list, 284
experimental, for severe pulmonary hypertension, 189
for hypertension treatment, 282–284
list, 284
for myasthenia gravis management, 270
preanesthetic, for teenagers, 49
psychotropic, list, 456–457
for rheumatoid arthritis, 266–267
for scleroderma management, 272
sensitivity to, in human immunodeficiency virus infection, 393
Meperidine, for analgesia in labor, in back pain patients, 236
Meralgia paresthetica, 141
Metabolic acidosis, in renal disease, and
anemia, 212
Metabolic problems, in liver disease, 465–466
Metabolic status, in acute renal failure, 209
Metabolic tolerance to drugs, defined, 403–404
Metabolism
of alcohol, 410
of cocaine, 417
Methadone, interaction with zidovudine, 415
Methadone maintenance, in pregnancy, 414–415
Methimazole, for hyperthyroidism in pregnancy, 219
Methylenedioxyamphetamine (MDMA) (ecstasy), 424
Methylergonovine (Methergine), 115–116
contraindication to, in maternal hypertension, 317
for managing uterine bleeding, in
amniotic fluid embolism, 359
for utero-tonsar therapy in hypertrophic cardiomyopathy, 173
Methylprednisolone, for short-term management of multiple sclerosis, 134
Methylprednisolone, for managing idiopathic thrombocytopenic purpura, 311
Metoclopramide, to stimulate gastric emptying, 500
Metoprolol, for controlling ventricular rate, in patients with atrial fibrillation or
flutter, 168
Michigan Alcohol Screening Test (MAST), 411
Microadenomas, pituitary, 228–229
Microangiopathy in pregnancy, 316–318
Microalbuminuria, in proteinuria, 188
Microembolization, hemodynamic changes due to respiration, 349
β2-Microglobulin, urinary, levels of and fetal renal function, 350
Midazolam, for induction of general anesthesia, 500
in a morbidly obese parturient, 62–63
in thyroid storm, 220
Migraine headache, 133
Minute ventilation, during pregnancy, 88, 143, 505–506
Misoprostol, to control excessive blood loss in placenta accreta, 103
postpartum, 116, 122
Mitrail regurgitation, 176–178
Mitrail stenosis (MS), 180–182
rheumatic, mortality in, 175, 512
Mitrail valve prolapse (MVP), 176–177
association with scoliosis, 235
Mobilization, of obese patients after surgery, 63
Monamine oxidase inhibitors (MAOIs), 455–458
Monitored anesthetic care (MAC), for cardioversion, 172
Monitoring antenatal for fetal well-being, 341
in postdate pregnancy, 304
of blood glucose in diabetic parturients, 338
of coagulopathy, in placental abruption, 94
during delivery, after myocardial infarction in pregnancy, 193
of Eisenmenger’s syndrome patients, 188
fetal, in adult respiratory distress syndrome, 147–148
of fetal heart rate patterns, electronic, 18
of heart transplant patients, 198
invasive
in acute renal failure, 209
during anesthesia in Addison disease, 225
during labor and delivery in cardiovascular disease, 163–164
in pheochromocytoma patients, 228
maternal
in placental abruption, 92
with pretreatment for fetal supraventricular tachycardia, 29
perioperative, in hepatic disease, 469
Monochorionic-diamniotic twins, twin-twin transfusion syndrome in, 79
Monochorionic twins, vascular communications between, 78–79
Mononeuropathies, in the parturient, management of, 140–141
Monozygotic twinning, 77
Mood disorders, 447–449
Morbidity
in antepartum thromboembolism, 371
in arteriography, 350
fetal, in insulin use to treat depression, 453
in myocardial infarction in pregnancy, 191
neonatal
in cytomegalovirus infection, 390
in herpes simplex virus infection, 393–394
in myasthenia gravis, 136
in pancreatitis in pregnancy, 223
perinatal, in fetal macrosomia, 306
in peripartum cardiomyopathy, 174
in rheumatic heart disease, 175–176
in venous cava interruption, 352
Morphine
as an alternative to monoamine oxidase inhibitors, 458
subarachnoid, postpartum and postoperative use of, 49–50
Mortality
in acute fatty liver of pregnancy, 511
in acute respiratory distress syndrome, 507
in adult respiratory distress syndrome, 147
in aortic insufficiency, 28
in agranulocytosis from clozapine, 458
in amniotic fluid embolism, 355
anesthetic-related, during delivery, 49
in antepartum thromboembolism, 371
in aortic stenosis, 180
in bipolar disorder, 448–449
perinatal, 8
associated with maternal cystic fibrosis, 150
in breech presentation, 67–68
in compound presentation, 77
in face presentation, 76
in fetal macrosomia, 306
in fulminant hepatic failure, 481
in hyperadrenocorticism, 225
from *Listeria* infection, 394
in preterm infants, comparison of delivery procedures, 295–296
due to tobacco exposure, 407, 425
with warfarin versus heparin use, 161
in peripartum cardiomyopathy, 174
in pheochromocytoma, 226
in rheumatic heart disease, 175
in septic shock, 440
for singletons, twins and triplets, comparison, 82
in twin-twin transfusion syndrome, 79
in uterine inversion, 123
in vena cava interruption, 352
Mother
anesthetic management of, in fetal interventions, 38–39
condition of, and anesthesia after failed intubation, 62
infection in, when twins are delivered by cesarean section, 81
risk to, in twinning, 78
Multidisciplinary team, for monitoring pregnancy
in Eisenmenger’s syndrome patients, 187
in pheochromocytoma, 196
Multifetal gestation, 77–84
management of fetal death, with one or more survivors, 523–524
Multiorgan failure (MOF), association with adult respiratory distress syndrome, 147
Multiple-gestation pregnancy, morbidity and mortality in, 517
Multiple sclerosis, 134–135
Muscle relaxants
cautions about use of, in myasthenia gravis, 270
interaction with cocaine, 422
reversal of, in renal disease patients, 213–214
Muscle rigidity, as a sign of malignant hyperthermia, during labor, 248
Muscular disease, 133–142
Muscular dystrophy, 137
Mutations
deletional, in *α*-thalassemia, 254–256
prothrombin G20210A polymorphism, 325–326
spontaneous, in achondroplasia, 236
See also Congenital abnormalities/disorders
Myasthenia gravis (MG), 135–136, 269–271
neonatal, prevalence with maternal myasthenia gravis, 269
*Mycobacterium tuberculosis*, infection by, 398
Myeloblastosis (MMC), 38
Myocardial function, fetal, 2
Myocardial infarction (MI)
association with nifedipine use for cocaine toxicity, 421–422
during pregnancy, causes of, 190–194
Myocardial ischemia
causes of, during pregnancy, 190
symptoms of, in cardiac transplant patients, 198
Myocardium, diseases of, 172–175
Myometrium
devascularization of, survival after delivery, 111
devascularization of, survival after delivery, 118–119
Myopathy, association with malignant hyperthermia, 246–247
Myotonic disorders, 136–137
N
Nalbufene, reversal of narcotic intoxication with, 413
Naloxone, reversal of intoxication with, 412–413
Narcotics, abuse of, and pregnancy, 413–416. See also Drug abuse
National Center for Health Statistics, 8
fetal death as defined by, 515
National Heart, Lung, and Blood Institute, workshop on peripartum cardiomyopathy, 173–175
National High Blood Pressure Education Program, preeclampsia defined by, 316
National Institute of Child Health and Human Development (NICHD)
Diabetes in Early Pregnancy project, 338
Maternal-Fetal Medicine Units Network, on training for vaginal breech delivery, 67
National Institute on Drug Abuse (NIDA), estimate of illicit drug use during pregnancy, 522
National Institutes of Health
consensus definition of obesity, 53
Heart, Lung, and Blood Institute, evaluation of autologous transfusion, 100
Natural childbirth, for the obese mother, 58–59
Neonatal abstinence syndrome, 407
in narcotic abuse, 414
Neonatal effects
of cocaine, 420–421
drug abuse, 407–408
Neonatal effects *(Continued)*

- of ethanol, 412
- of marijuana, 416
- of tobacco smoking, 425

Neonatal purpura fulminans, 326

Neonate, transition to, from the fetal state, 7–8

Nephrolithiasis, urinary tract obstruction due to, 211

Nephropathy, diabetic, special monitoring for patients with, 343–344

Nephrotic syndrome, association with preeclampsia, 324

Neural tube defects, maternal serum analysis to detect, 9–10, 27

Neuraxial block
  - caution about, for hypertrophic cardiomyopathy patients, 173
  - for cesarean delivery in Eisenmenger’s syndrome patients, 188

Neurobehavioral testing, assessing the effects of cocaine use, 421

Neuroleptic malignant syndrome *(NMS)*, 459

  - phenothiazines as triggers for, 247

Neurologic disease/dysfunction, 133–142

Neurologic disease/dysfunction, 133–142

- of the febrile parturient, 433–434
- in hypertension, in preeclampsia, 510
- for intrapartum fetal distress due to uterine hyperactivity, 497
- for tocolysis, 299
- for uterine and cervical relaxation, 75 in multiple deliveries, 83
- for uterine inversion management, 129
- Nonimmune hydrops fetalis *(NIHF)*, pathogenesis of, 253
- Non-mood disorders, 449
- Nonassessing fetal status defined, 18
  - as an indication for cesarean delivery, 293
- Nonsteroidal antiinflammatory drugs *(NSAIDs)*, 266
  - effect of, on postoperative analgesic requirements, 306
- Nonstress test *(NST)*
  - for monitoring diabetic parturients, 341
  - to predict fetal outcome, 11–12

  - Norcocaine, product of cocaine metabolism, 417
- Norinephrine, effects on heart rate, 5
- North American Malignant Hyperthermia Group, protocol for testing, 245
- Nuchal translucency *(NT)*, in Bart’s hydrops fetalis, 260

O

Obesity
defined, 53
- morbid, in the pregnant woman, 53–66
  - as a risk factor for postdate pregnancy, 305

Oblique presentation, vaginal delivery in, 70–71

Obsessive/compulsive disorders, managing in pregnancy, 449

Obstetric management
  - in achondroplasia, 236
  - in acute fatty liver of pregnancy, 474
  - in acute hepatic failure, 469–470
  - in Addison disease, 225
  - in adult respiratory distress syndrome, 147–148
  - in aloimmune thrombocytopenia, 315–316
  - in anemia, 358–360
  - in amniotic fluid embolism, 421–422
  - in anticoagulation, 374–375
  - in antiphospholipid syndrome, 269, 324–325
  - in aortic insufficiency, 178
  - in aortic stenosis, 180
  - in asthma during pregnancy, 146
  - in autoimmune hemolytic anemia, 275–276

in backache, 234
- in barbiturate addiction, 413
- in Bell’s palsy, 140
- in Bernard-Soulier syndrome, 314
- in brain neoplasms, 138
- in cardiac transplant, maternal, 197
- in cardiovascular disease, 162
- in hypertrophic cardiomyopathy, 172–173
- in carpal tunnel syndrome, 140
- in cerebral hemorrhage, 139
- in cholecystitis, 483
- in cocaine abuse, 421
- of complications related to protein S, protein C and antithrombin III deficiencies, 326
- of congenital abnormalities, 28
- in cortical vein thrombosis, 139–140
- in cystic fibrosis, 139–140
- in dermatoangiomatosis/polymyositis, 271
- in diabetes insipidus, 229
- in diabetic parturients, 338–341
- in disseminated intravascular coagulation, 319
- in drug abuse, 408–409
- in Eisenmenger’s syndrome, 187
- in epilepsy, 135
- in ethanol abuse, 412
- in factor V Leiden, 325
- in factor XI deficiency, 321
- of the febrile parturient, 433–434
- in fetal distress, 495–497
- in gestational thrombocytopenia, 310
- in Glanzmann’s thrombasthenia, 315
- in headache during pregnancy, 133–134
- of heart transplant patients, 197–198
- in HELLP syndrome, 316–317, 473
- in hemophilia A, 320
- in hemorrhage, 508
- in hepatic disease, 467
- in hepatic hematoma, 472
- in hydrocephalus, maternal, 140
- in hyperadrenocorticism, 225
- in hyperemesis gravidarum, 482
- in hyperparathyroidism, 223
- in hyperthyroidism, 219
- in hypoparathyroidism, 224
- in hypothyroidism, 221
- in idiopathic thrombocytopenic purpura, 275, 311
- in inherited thrombophilias, 327
- in intrahepatic cholestasis of pregnancy, 482
- in intrauterine fetal demise, 523–524
- in iron deficiency anemia, 321–322
- in liver transplantation in pregnancy, 484
- in lupus anticoagulant presence, 324
- in Marfan syndrome, 194
- in marijuana use, 416–417
in maternal tetralogy of Fallot, 186
in meralgia paresthetica, 141
in mitral regurgitation, 177
in mitral stenosis, 181–182
in mitral valve prolapse, 176
in multiple sclerosis, 134
in muscular dystrophy, 137
in myasthenia gravis, 136, 270
in myocardial infarction, intrapartum, 192
in myotonic disorders, 136–137
in narcotic abuse, 414–415
of the obese patient, 57–58
in panhypopituitarism, 230
in peripartum cardiomyopathy, 175
in pheochromocytoma, 197, 227
in phencyclidine use, 423–424
in placenta accreta, antepartum, 103
in placental abruption, 91
in placenta previa, 96–97
in postdate pregnancy, 303–304
in postpartum hemorrhage, 116–123
in preeclampsia, 284–286
with hepatic involvement, 471
in preterm labor, 292–295
in primary pulmonary hypertension, 189
in prolactinomas, 229
in psychotropic drug use, 454–460
in pulmonary embolism, 350–352
in retained placenta, 121–122
in rheumatoid arthritis, 266
in scleroderma, 272–273
in scoliosis, 235
in sickle cell disease, 322
in smoking during pregnancy, 149–150
in spinal cord injuries, 138
in systemic lupus erythematosus, 267–268
of teenagers, 47–48
in thalassemia, 323
in thrombotic thrombocytopenia purpura and hemolytic uremic syndrome, 318
in tobacco use, 425–426
in trauma to the pregnant woman, 241–242
in uterine atony, 101–102, 120–121
in uterine inversion, 123
in uterine rupture, 105
in vasa previa, 101
in venous air embolism, 362–363
in von Willebrand’s disease patients, 313–314
Occupational exposure, and fetal death, 523
Olanzapine, 458
Oligohydramnios, association with fetal growth restriction, 519
Opioid-based anesthesia for patients with cardiac transplants, 198
for patients with cardiovascular disease, 164–165
for patients with Eisenmenger’s syndrome, 188–189
Opioids intravenous postoperative, for renal disease patients, 214
for postpartum pain, 306
Orthopedic problems, 233–244
Osteogenesis imperfecta, 236
Osteoporosis, risk of, in heparin therapy, 161
Outcomes of breech deliveries, vaginal and cesarean, 68–69
of congenital heart disease, maternal, 183–184
of maternal narcotic abuse, 414
perinatal of fetal cocaine exposure, 420
of maternal congenital heart disease, 184
of scoliosis in pregnancy, 235
of spinal or epidural bleeding, 376
Oxygen/oxygenation consumption of, 193
during parturition, 158
during pregnancy, 143, 505
fetal, 506
and placental respiratory gas exchange, 3–4
during labor, for patients with mitral valve prolapse, 177
maternal, 496
partial pressure of, in pregnancy and obesity, 55–56
transport of to the fetus, steps in, 3–4
relationship with glycosylation of hemoglobin, 333–334
and uterine uptake, 4
Oxygen therapy for managing labor and delivery in cystic fibrosis, 150
for managing pulmonary embolism, 350–352
Oxyhemoglobin dissociation curves, fetal versus maternal, 4–5
Oxytocin effect of on postpartum hemorrhage, 114–115
on uterine contraction in the fourth stage of labor, 112
on uterine rupture rates, 104
in obstetric management of postpartum hemorrhage, 117, 120–121
prophylactic administration of, 80–81
in placenta accreta, 103
study of reduced blood loss in, 122
P
Pacemakers intrinsic, of the fetus, 5
maternal, effect on fetal bradycardia, 170
Pain chest, in venous air embolism, 362
control of, in early labor with stillbirth, 450
in neonates, 41
postpartum, association with fetal macrosomia, 305–306
and posttraumatic stress disorder, 451–452
See also Analgesia; Anesthesia Pancreatic insufficiency, association with cystic fibrosis, 150
Panhypopituitarism, 229–230
Panic disorders, managing in pregnancy, 449
Panniculus, cephalad retraction of, in morbidly obese parturients, 61
Parathyroid disease, 222–224
Parathyroid hormone (PTH), 222
Paroxysmal supraventricular tachycardia, adenosine for treating, 170–171
Partial thromboplastin time (PTT), maintaining a target level of in labor and delivery, 353
Parturition, cardiovascular effects of, 158
Parvovirus B19 infection, 395
association with fetal loss, 517
Patent ductus arteriosus, effects of, in pregnancy, 185
Patent foramen ovale, “paradoxical” embolism in, 363
Pathogenesis of fever, 433
of peripartum cardiomyopathy, 174
of septic shock, 440
Pathology, placental, and fetal death, 517–519
Pathophysiology of amniotic fluid embolism, 356–357
of antiphospholipid syndrome, 268–269
of aortic insufficiency, 178
of aortic stenosis, 179
of autoimmune hemolytic anemia, 275
of Bell’s palsy, 140
of brain neoplasms, 138
of cerebral venous thrombosis, 139–140
of cholecystitis, 483
of choledochal cyst, 481–482
of cocaine use, 418–419
of cystic fibrosis, 150
of dermatomyositis, 271
of Eisenmenger’s syndrome, 186–187
of epilepsy, 135
of ethanol abuse, 410–411
of fetal congenital abnormalities, 27
α-thalassemia, 254–255
Pathophysiology (Continued)
Placental perfusion, changes in diabetic women, 333
Placental thrombosis, antiphospholipid antibodies associated with, 324
Placental transfer, of cocaine, alcohol, and tobacco, 406
Placenta percreta, defined, 102–104
Placenta previa, 94–100
as a cause of fetal death, 518
as a cause of third trimester hemorrhage, 87
epilepsy associated with, 135
placenta accreta associated with, 121
in smokers, 150
and uterine artery ligation to control hemorrhage, 120
venous air embolism associated with, 361
Placenta, of twins, 77–80
Planning
for crises, in pregnancy accompanied by cardiovascular disease, 159–160
for postpartum hemorrhage management, 114
preanesthetic preparation for parturients with renal disease, 212
Plasma concentrate, for treating von Willenbrand’s disease, Types 2 and 3, 313
Plasmapheresis, in thrombotic thrombocytopenia purpura (TTP), 318
Plasma volume, expansion of, in preeclampsia, 285–286
Platelets
count of
and choice of anesthetic, 286–287
in idiopathic thrombocytopenic purpura, 274
for monitoring hemolytic uremic, and thrombotic thrombocytopenic purpura, 281
disorders of, in pregnancy, 310–316
donor, indications for transfusing in postpartum hemorrhage, 127
dysfunction in relationship with thyroid deficiency, 221
reversible, from indomethacin, 299
effects of, in primary hemostasis, 309–310
secretion of, disorders in, 315
Pneumonia, in pregnancy, 148–149, 440
Polymerase chain reaction techniques, for diagnosing β-thalassemia, 259
Polymyositis (PM), 271–272
Portal hypertension, in pregnancy, 478–479
Positional change, and venous air embolism, 361
Positional hypotension, in pregnancy, 157–158
Positioning, maternal, effect on fetal distress, 496
Positive end-expiratory pressure (PEEP), to improve oxygenation in obese patients, 63
Postdate pregnancy, 303–307
Postdelivery care
for the neonate, in preterm delivery, 300
in preeclampsia, 288–289
Postoperative care, of morbidity in obese patients, 63–64
Postpartum back pain (PPBP), 233
Postpartum care
blood transfusion, indications for, 120
in diabetic parturients, 344
in Eisenmenger’s syndrome patients, 189
in malignant hyperthermia, 250–251
for teenagers, 49–50
Postpartum depression
risk factors for, 447
tension headache as a marker for, 133
Postpartum endometritis, treating in pregnancy, 387
Postpartum hemorrhage, 111–132
secondary, 114
Postpartum hysterectomy, indications for, 120
Postpartum psychosis, 449–450
Postrenal etiology, for acute renal failure, 209
Posttraumatic stress disorder, after trauma, 239
Postpartum back pain (PPBP), 233
Postpartum endometritis, treating in pregnancy, 387
Postpartum hemorrhage, 111–132
secondary, 114
Postpartum hysterectomy, indications for, 120
Postpartum psychosis, 449–450
Posttraumatic stress disorder, for acute renal failure, 209
Potassium, alteration of levels of, in prematurity
associated with, 437–438
Pottery, incidence of, in obese pregnant women, 56
of smoking, 406
of venous air embolism, 361
Preexcitation syndromes, 168–170
Pregnancy
adolescent, 451
effects on
of amphetamine use, 423
of ankylosing spondylitis, 273
of cocaine use, 418–419
of marijuana use, 416
of phencyclidine use, 423
effects of
on antiphospholipid syndrome, 268
on myasthenia gravis, 269
on polyclonitis/dermatomyositis, 271
on rheumatoid arthritis, 265
on systemic lupus erythematosus, 267
on Takayasu arteritis, 195
and ethanol abuse, 411–412
implications in
of asthma, 144
of obesity, 55–56
postmature, risk to the fetus in, 519
in renal transplant patients, 211
in scleroderma, 272
Pregnancy-induced hypertension (PIH)
obesity associated with, 56
perinatal mortality associated with, 8
Prehospital care, after trauma, 239
Premature mortality associated with, 437–438
Prematurity
association of
with malpresentation, 67
with primary pulmonary hypertension, 189
with retained placenta, 122
with sexually transmitted diseases, 47
and perinatal morbidity
in multiple gestations, 81–82
in twins, 78
and perinatal mortality, 8
Prenatal care
for adolescents, 46
for drug-abusing parturients, 408–409
in opiate abuse, 414
Prenatal diagnosis
of Bart’s hydrops, 260–261
of fetal disorders, 23–26
Prepartum monitoring, 1–22

for managing uterine atony, 117, 120–121
Prostaglandins
- circulating, in the fetus, 3
  - E₁ analogue of, for treating postpartum hemorrhage, 116, 122
depletion of, by alcohol, 410
  - E₂ effect on fetal breathing movements, 5
effect on uterine contraction, 299
F₂α effect on asthmatic patients, 146
for primary pulmonary hypertension management, 189
release of, in burn injury, 241
Prostamine, to reverse heparin activity, 351–352, 373
Protein C activated, resistance to, due to factor V Leiden, 325, 369–370
deficiency of, and hypercoagulability, 326, 522
Protein S, deficiency of, and hypercoagulability, 326, 522
Prothrombin G20210A polymorphism, 325–326
Prothrombin time, increase in, in dilutional coagulopathy, 127
Protocol
culture-based, for treating Group B β-hemolytic streptococcus, 386
for heparin therapy, continuous, 351
risk factor-based, for treating Group B β-hemolytic streptococcus, 386
See also Algorithms
Pseudaneurysms, postpartum hemorrhage caused by, 117–118
Pseudocyesis, 452
Pseudomonas aeruginosa, infection by, 480
association with cystic fibrosis, 150
Psychiatric disease, 447–462
Psychologic issues, in fetal death, 525
Psychosocial effects
- of drug use in pregnancy, 406
  - in support for pregnant teenagers, 48
Nutrition, role of, 473
Puercerium
- cardiovascular changes in, 158–159
  - venous air embolism in, 361
Pulmonary angiography, for diagnosing pulmonary embolism, 370
Pulmonary artery catheter, for monitoring in cardiovascular disease, 163–164
in Eisenmenger’s syndrome, contraindications to, 188
in primary pulmonary hypertension, 190
Pulmonary artery thromboembolectomy, in amniotic fluid embolism, for treating postpartum shock, 359
Pulmonary capillary wedge pressure (PCWP), for measuring hemodynamic trends, in mitral stenosis patients, 182
Pulmonary changes
- in morbid obesity, 54
  - in pregnancy, and trauma, 238
Pulmonary edema
- from β-agonists, 297–298
- in amniotic fluid embolism, 357
- in hepatic disease, postpartum development of, 473
- in obstetric patients receiving nitroglycerin, 39
- in obstetric patients with mitral stenosis, 181
Pulmonary embolism
- causes of, in pregnancy, 369
detecting, with a ventilation/perfusion scan, 350
- incidence of, during pregnancy, 347, 370
  - in obese patients after surgery, 63
Pulmonary function, impairment in scoliosis, 235
Pulmonary hypertension
- in amniotic fluid embolism, 356
  - as a complication of portal hypertension, 480
  - primary, 189–190
  - secondary, 186–189
See also Eisenmenger’s syndrome, 187–188
Pulmonary vascular resistance (PVR), in Eisenmenger’s syndrome, 186–187
Pulmonary vasodilator therapy, for primary pulmonary hypertension, 189
Pulmonic stenosis, 182
Pulse oximetry, for monitoring in cardiovascular disease, 163
in Eisenmenger’s syndrome, 188
of fetal heart rate, 19
of fetal heart rate during surgery, 41
of fetal scalp pH, 494–495
of obese women, 57–60
Pyelonephritis, in pregnancy, 210
symptoms of, 439–440
Pyelonephritis, treating in pregnancy, 387
Pyridostigmine (Mestinon), for myasthenia gravis treatment, 136
Pyridoxine, for preventing peripheral neuropathy in isoniazid treatment, 398
Pyrogens, exogenous and endogenous, 433
Q
- QT syndrome, long, risks of, 170
Quinalones, contraindication to, in pregnancy, 210
Index

Quinidine
for controlling ventricular rate, 168
for treating atrial tachycardia, 168

R
Race
and fetal death rate, 515
and risk of preeclampsia, 47
and teenaged birthrate, 45

Radiation, exposure to
while placing an implantable cardioveter-defibrillator, 172
during pregnancy, 506–507
and studies of the causes of fever, 434

Radiofrequency thermal ablation, for
treating fetal lung masses, 34–35

Radiologic evaluation, in trauma to the pregnant woman, 239

Radiouclide venography, with 99mtechnetium particles, to detect deep venous thrombosis, 350

Receptors, for oxytocin, changes in during pregnancy, 114–115

Red cell indices, of α-thalassemia, 256

Regional anesthesia
for anticoagulated parturients, 354
for aortic insufficiency patients, 179
for aortic stenosis patients, 180
in cardiovascular disease, 164–165
for cesarean delivery, 49
in myasthenia gravis, 270
in tetralogy of Fallot, 186
for delivery in Marfan syndrome, 194
for the febrile parturient, 434–437
in human immunodeficiency virus infection, 441–442
in hypoparathyroidism, 224
in myasthenia gravis, 136
in myocardial infarction, 193
in preeclampsia, 281–282
See also Analgesia, regional

Remifentanil
for cesarean delivery, in women with cardiovascular disease, 165
for coarctation of the aorta patients, 195
for Eisenmenger’s syndrome patients, 188

Renal blood flow (RBF), increase in, during pregnancy, 207–208

Renal changes
in preeclampsia, 509
in pregnancy, 506

Renal crisis, in scleroderma patients, 272

Renal development, effect on, of angiotensin converting enzyme inhibitors, 282–283

Renal disease, 207–215
irreversible, in systemic lupus erythematosus, 267
nephrogenic diabetes insipidus, 229
reversible, in premature infants, due to nonsteroidal antiinflammatory drugs, 266

Renal failure
acute, in placental abruption, 92–93
in hepatic disease, 465–466
in hepatorenal syndrome, 479

Renal parenchymal disease, classification of, 209–210

Renal transplants, 211
diabetic recipients of, 344

Renin-angiotensin system, fetal, 3

Respiratory distress syndrome (RDS)
for venous thromboembolism, 370

Respiration, changes in
at delivery, 7–8
in hypothyroidism, and anesthetic management, 221
and obesity, in pregnancy, 54–56
in preeclampsia, 509–510
in pregnancy, 505–506
in pulmonary thromboembolism, 349

Respiratory disease, 143–153
association with ankylosing spondylitis, 274
managing infections in pregnancy, 507

Resuscitation
in amniotic fluid embolism, 359
cardiopulmonary, during pregnancy, 167–168
neonatal, for infants of diabetic mothers, 341
perinatal mortality associated with, 8
predicting, with surfactant measurements, 10

Resuscitation
in ankylosing spondylitis, 123

Rheumatic fever
aortic insufficiency subsequent to, 178
and heart disease, 175–176

Rheumatic heart disease (RHD)
decline in, 155
mitral stenosis associated with, 180–181
Rheumatoid arthritis, 265–266
Rheumatologic diseases, and risk of fetal death, 519–520

Rifampin
for treating tuberculosis, 398
for rapid induction of anesthesia, in malignant hyperthermia susceptibility, 250

Risk factors
for adolescent pregnancy, 45–51
for adverse perinatal outcome, due to maternal obesity, 53
for alloimmune thrombocytopenia, 315–316
for anamnestic fluid embolism, 355
for coronary artery disease, in pregnant women, 190
for eclampsia, 279
for fetal distress, 493–495
for gestational diabetes, 340
for hypereosinophilia, 482
for peripartum cardiomyopathy, 174
for placenta accreta, 102
for placental abruption, 90
for placenta previa, 95
for preeclampsia, 279, 508
for preterm birth, 291–292
for shoulder dystocia, 305–306
for spinal-epidural hematoma, 375
for thromboembolism, 347, 352–353, 370
venous, list, 348
for thrombosis, protein S and protein C deficiencies, 326
for uterine atony, 101
for uterine rupture, 104–105
for vasa previa, 100
for venous thromboembolism, 369–370

Risks
of amniocentesis and chorionic villus sampling, 24–25
of cardiovascular disease
effect on choice of anesthesia, 165–166
in pregnant women, stratification, 156
of hemorrhage from a retained placenta, 122
of heparin use in pregnancy, 372
of infectious disease transmission by blood transfusion, 126
in drifting, 78–80
in uterine rupture, in spontaneous versus induced labor, 104

Risperidone, 458

Ristocetin-induced platelet aggregation (RIPA), for von Willenbrand’s disease, 312

Ritodrine
for managing acute fetal distress, 496
maternal side effects in use of, 297

Rocuronium
metabolic profile of, in hepatic disease, 468

Right ventricle, air trapped in, in venous air embolism, 361–362

Roglutide, 458

Rocuronium
metabolic profile of, in hepatic disease, 468

Rocuronium
for rapid induction of anesthesia, in malignant hyperthermia susceptibility, 250

Rocuronium
metabolic profile of, in hepatic disease, 468
of fetal anomalies, 33–38
of hyperadrenocorticism, 225
of mitral stenosis, 181
of pheochromocytoma, 196–197, 227
of postpartum hemorrhage management, 118–119
of tetralogy of Fallot, 185–186
of uterine atony, 101
for weight reduction, fertility and pregnancy rates following, 57
Surveillance, fetal, in managing asthma, 146
Suxamethonium, atypical response to, in
Swedish Medical Birth Registry, data on
Systemic inflammatory response syndrome, 163–166
association with neuraxial local anesthetics-induced, 165–166
for weight reduction, fertility and pregnancy rates following, 57
Sympathectomy
anesthesia-induced, 165–166
association with neuraxial local anesthetics, 124
Sympathetic nervous system, effect of, on
Swedish Medical Birth Registry, data on
T
Tachycardia
with β1- and β2-adrenergic agonists, 297
fetal, causes of, 14
oxygen demand in, 193
reflex, in decreased venous return due to hemorrhage, 124
supraventricular, in utero conversion of, drugs for, 29
Takayasu arteritis (TA), 195
Teenagers, pregnant, 45–51
Temperature
fetal, regulation of, 6–7
maternal
monitoring in cardiovascular disease, 163
regulation of, 433
regulation of, in regional anesthesia, 435
Teratogenic agents
carbamazepine, 460
cyclophosphamide, 267
exposure to, and normal fetal growth, 39
infections as, 381–382
monoamine oxidase inhibitors as, 374
phenytoin, 171
valproic acid, 460
Terbutaline
for acute fetal distress, 496
maternal side effects in use of, 297
for pulmonary complications in amniotic fluid embolism, 359
Termination of pregnancy, in
Thalassemias, 323
α-, 253–264
β-, management of, 261
association with neuraxial local anesthetics-induced, 165–166
for weight reduction, fertility and pregnancy rates following, 57
Systemic lupus erythematosus (SLE), 267–268
anticardiolipin antibodies syndrome associated with, 325
placental insufficiency in, 518
pregnancy outcome in, 519–520
Systemic vascular resistance, 89
Thiopentone
for convulsions in preeclampsia, 287–288
for induction of general anesthesia in a morbidly obese parturient, 62
Thiophixene, 458
Thompson, Tommy G., on community grants to manage teenaged pregnancies, 451
Thoracic motor function, effect on, of spinal anesthesia, 61
Thoracotomy, in maternal cardiac arrest, 168
Thromboaoortopathy, occlusive, 195
Thrombocytopenia
association of, with cocaine use, 419
in Bernard-Soulier syndrome, 314
fetal, in human immunodeficiency virus infection, 392
fetal alloimmune, in maternal Glanzmann’s thrombasthenia, 315
in heparinized patients, 372
in pregnancy, 310–311
incidence of, 288
in von Willenbrand’s disease, Type 2B, 313
Thromboelastogram (TEG)
for assessing anticoagulation due to low molecular weight heparin use, 374
for assessing anticoagulation status, 377–378
for assessing coagulation defects, 94
for assessing functional hemostasis, 89
effects of platelet count, 287
in preeclampsia, 317
for measuring platelet function, in patients on aspirin therapy, 266
R-time, correlation with heparin test results, 328
Thromboembolic disease, 347–354
Thromboembolism, association of with Eisenmenger’s syndrome, 187
with mitral regurgitation, in pregnancy, 177
with mitral stenosis, 181
with primary pulmonary hypertension, 189
with prosthetic valves, 182
Thrombolysis, in management of acute myocardial infarction, 192
Thrombophilias, 323–326
Thrombophlebitis, risk factors for, in pregnancy, 348
Thromboprophylaxis, 352–353
Thrombosis, factors in the development of, 369–380
Thrombotic microangiopathy, 318
Thrombotic pulmonary embolism, differentiating from amniotic fluid embolism, 358
Transjugular intrahepatic portal-systemic (TIPS), 318
Thyroid diseases/disorders, 217–218
  association with fetal death, 520–521
  thymomas, association with myasthenia gravis, 135–136
  thyroid storm in pregnancy, 219–220
Thyroidectomy, hypoparathyroidism subsequent to, 223
Thyroxin, for panhypopituitarism patients during pregnancy, 230
Thyroxine-binding globulin (TBG), elevation of levels of, during pregnancy, 217–218
Tidal volume ventilation, for obese patients, 63
Timing, of the delivery of a second twin, 81
Tissue plasminogen activator (TPA), intrapartum therapy with, in myocardial infarction in pregnancy, 192
Tobacco abuse, 424–426
  association with depressive symptoms, 447
See also Smoking
Tocotylosis/tocolytic agents
  contraindications to, in trauma to the pregnant woman, 242
  for fetal distress management, 496–497
  interaction of agents for, with anesthetics, 297–299
  list, with dosage and side effects, 294
  in placenta previa with hemorrhage, 96–97
  in preterm labor, 292–295
Tolerance, to drugs, defined, 403–404
Toxicity
  of amniotic fluid, 356–357
  of halothane, enflurane, isoflurane, and sevoflurane, 468–469
  of isoniazid, 398
Toxoplasma gondii, infection by, 397–398
Toxoplasmosis, 397–398
  congenital, percutaneous umbilical blood sampling to detect, 28
  Transcutaneous electrical nerve stimulation (TENS), in treating lower back pain, 234
  Transfusion
  in amniotic fluid embolism management, 359
  of blood products, in disseminated intravascular coagulation, 319
  incidence of reactions to, 126
  of platelets, in HELLP syndrome, before delivery, 317
  in postpartum hemorrhage, 125–127
  Transjugular intrahepatic portal-systemic shunts (TIPSS), to reduce esophageal venous pressures, 479
  Transmission
  of hepatitis B to the fetus, 475
  of hepatitis C to the fetus, 476
  of parvovirus B19, transplacental, 395
  Transplantation, liver, and pregnancy, 484–486
  Transverse presentation, mortality in, 70–71
  Trauma
  adult respiratory distress syndrome associated with, 147–148
  mortality due to, fetal and maternal, 523
  in the pregnant woman, 237–243, 510
  Treponema pallidum, infection by, 396–397
  Trial of labor (TOL), 104–105
  Tricuspid regurgitation, 178–179
  Tricuspid valve, streaming control by, 2
  Tricyclic antidepressants, studies of effects on the fetus, 455
  Trimethoprim with sulfur, effect on the fetus, 210
  Triple screen test, 10
  defined, 25
  to predict risk of fetal congenital abnormalities, 31
  Trisomy
  13, malformations in, 23
  18
  malformations in, 23
  21
  maternal serum screening to detect, 27
  as a cause of fetal death, 516
  See also Chromosomes/chromosomal abnormalities; Down syndrome
  Trophoblastic disease, gestational, 217–218
  Troussseau sign, in hypoparathyroidism, 224
  Tuberculosis, treating in pregnancy, 389, 398
  Turner’s syndrome
  chromosome distribution in, 23
  fetal death due to, 516
  Twins, 77–81
  Twin-to-twin transfusion syndrome (TTS), 37–38, 79
  risks to the mother and a surviving twin in, 517
U
  Ultrasonography
    Doppler
to detect air embolism, 362
to detect popliteal, femoral, or iliac thromboses, 350
  for fetal assessment, 494
  for fetal assessment, 9–11, 23–24
  in Bart’s hydrops fetalis, 260
  of congenital abnormalities, 27–28
detection of cardiac movement, 516
establishing gestational age, 303
in fetal hydrops, 30
for malpresentation confirmation, 67
in multiple gestation, 80
in trauma to the pregnant woman, 239
in vasa previa, 100–101
for pheochromocytoma diagnosis, 226
for placental fragment identification and removal, 117
placental separation phases observed with, 121
for placenta previa diagnosis, 96
real-time, for diagnosing deep venous thrombosis, 370
renal, for confirming nephrolithiasis, 211
for thyroid visualization, 217
transvaginal, to identify placenta accreta, 121
Umbilical blood sampling, percutaneous, 9
Umbilical cord accidents, fetal death due to, 518
Umbilical vein, oxygen saturation in the blood of, 1–2
University of Michigan Health System, anesthetic management for teenaged mothers at, 48
Urethral valves, endoscopic ablation of, in fetal obstructive uropathy, 33–34
Urinary system
  changes in, during pregnancy, 207–208
  infections of, 433–434, 439–440
  Urine output, as an indicator for extent of hemorrhage, 87
Urokinase, for thrombolytic therapy, 352
Urolithiasis, urinary tract obstruction due to, 210
Uropathy, fetal obstructive, surgical management of, 33–34
Uterine artery, ligation of, in postpartum hemorrhage, 120–121
Uterine atony, 101–102
  hemorrhage due to, 112–113
  postpartum, 120–121
Uterine artery ligation
  management of, 128
  outcome of hypogastric ligation in women with, 119
Uterine contractions
  effect of dantrolene on, 249
  in ergot alkaloid administration, 115–116
  and fetal assessment and monitoring, 10
  pharmacologic manipulation of, 297–298
  precipitation of autonomic hyperreflexia by, in patients with spinal cord injury, 138
Uterine inversion, 123
management of, 129

Uterine manipulation
association with venous air embolism, 361
for uterine atony, 101

Uterine packing, in postpartum hemorrhage, 117

Uterine relaxation
agents causing, withdrawal in postpartum hemorrhage, 121
in general anesthesia, 39
to permit delivery
in fetal head entrapment, 70
in multiple gestations, avoiding early placental separation, 83

Uterine retraction, and hemostasis, 112

Uterine rupture, 104–105
fetal mortality in, 238–239

Uterine vessels
laceration of, in amniotic fluid embolism, 356
vulnerability to air embolism, 361

Uteroplacental effects
of cocaine, 419
of electroconvulsive therapy, 454
of narcotics, 414
of substance abuse, 406–407
of tobacco smoking, 425

Uteroplacental insufficiency, in diabetes, 333–334
intrauterine fetal demise due to, 518–519

Uterus, enlarged, as a cause of acute renal failure, 209

V
Vaginal delivery
analgesia during, in multiple gestations, 82–83
breech, 69–70
of a second twin, 81
after a cesarean delivery, 104

Vagus nerve, control of fetal heart rate through, 5

Valacyclovir, for herpes simplex virus infection, 393

Valproic acid, as a teratogen, 460

Valvular cardiac disease, 511–512

Varicella zoster virus (VZV), infection by, 399

Vasa previa, 100–101
fetal death in, 518

Vascular necrosis, panhypopituitarism due to, 229–230

Vascular steal syndrome, in sacrococcygeal teratoma, 37

Vasocclusion, in sickle cell disease, 322

Vasopressin, release of, in pregnancy, 207–208

Vecuronium, metabolic profile of, in hepatic disease, 468

Venography, ascending, to identify deep venous thrombi, 349

Venous flow, placenta to the fetal heart, 1–2

Venous thromboembolic disease, indications for anticoagulant therapy in pregnancy, 369–370

Ventilation, postoperative, in myasthenia gravis, 270

Ventilation/perfusion scan, for diagnosing pulmonary emboli, 350

Ventilatory failure, 507

Ventricular septal defect (VSD), effects of, in pregnancy, 184–185

Ventricular tachycardia, in pregnancy, 170

Verapamil
for controlling ventricular rate, in patients with atrial fibrillation or flutter, 168
effects of, on the fetus, 171
for treating atrial tachycardia, 168
potential risks of, 170

Vesicoamniotic shunting, percutaneous, in fetal obstructive uropathy, 33–34

Vesicostomy, fetoscopic, in fetal obstructive uropathy, 33–34

Viral infections, 441–443
Viral infections. See also Human immunodeficiency virus (HIV) infection

Virchow’s triad, of risk factors for thromboembolism, 347–348, 369

Vitamin K (phytonadione), reversal of warfarin with, 374

Volume replacement, for managing diabetic ketoacidosis, 336

Volume restriction, in preeclampsia, 285–286

von Willebrand’s disease, 312–314
relationship with thyroid deficiency, 221–222

von Willebrand’s factor
risk of postpartum hemorrhage in deficiency of, 127
synthesis and storage of, 312

Vulvovaginal candidiasis, treating in pregnancy, 387–388

W

Warfarin
benefits and risks of, during pregnancy, 369
for prosthetic heart valve patients, use in pregnancy, 183
risk of congenital malformation with use of, 160–161, 327, 351, 374
Water retention, normal, in pregnancy, 207–208

Western immunoblot test, for Lyme disease, 395

White’s classification of diabetes in pregnancy, 339–340
relationship with prematurity and hypertensive complications, 336

Wilson’s disease, managing in pregnancy, 478

Withdrawal from drugs
cocaine, 417
defined, 403–404
life-threatening responses in ethanol withdrawal, 410–411
narcotic, 413
neonatal from benzodiazepines, 459
due to maternal drug abuse, 407

Wolff-Parkinson-White syndrome, 168–170

World Health Organization (WHO)
definition of fetal death by, 515–528
study of misoprostol for prophylaxis against postpartum hemorrhage, 122
study of oxytocin for prophylaxis against postpartum hemorrhage, 103

Wright stain, for diagnosing vasa previa, 100–101

Z

Zidovudine, to reduce maternal transmission of human immunodeficiency virus to the fetus, 409, 415